| Entries |
| Document | Title | Date |
|---|
| 20080206328 | Hypocholesterolemic Compositions Comprising a Statin and an Antiflatulent Agent - The present invention relates to hypocholesterolemic compositions comprising statins plus antiflatulent agents. In particular the compositions of the present invention comprise a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, whether in free form or as pharmaceutically acceptable salts and hydrates thereof, plus an antiflatulent agent. selected from the group consisting of simethicone and dimethicone. The combination of statins plus antiflatulent agents is useful in the prevention and management of flatulence caused by statins. | 08-28-2008 |
| 20080206329 | Modified Release Ciprofloxacin Compositions - Controlled release tablets comprising ciprofloxacin, with hardness and friability of the said tablets ranges between 10 to 70 kiloponds and less than 2% respectively, the compositions releasing at least 80 percent of the total amount of the ciprofloxacin into a pH 1.2 aqueous dissolution medium within about 1 hour. | 08-28-2008 |
| 20080206330 | Pharmaceutical Composition - Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity. | 08-28-2008 |
| 20080213360 | DRY GRANULATION BINDERS, PRODUCTS, AND USE THEREOF - A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active, an microcrystalline cellulose containing material, and, optionally other pharmaceutically acceptable excipients. The microcrystalline cellulose containing material has a maximum primary compaction tensile strength of at least 9 MPa or at least 9.5 MPa and a secondary compaction tensile strength of at least 5 MPa, at least 5.5 MPa, or at least 6 MPa. A method for evaluating binders is also disclosed. | 09-04-2008 |
| 20080213361 | Method for Production of Directly Compressible Ibuprofen Formulations - A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m | 09-04-2008 |
| 20080220059 | Pharmaceutical preparation of
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide - The invention relates to a pharmaceutical preparation for oral administration comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide or its hydrates and/or solvates, as well as an acid, a method for its production as well as the use of this preparation for the treatment and/or prophylaxis of diseases which are caused by herpes viruses, in particular diseases which are caused herpes simplex viruses. | 09-11-2008 |
| 20080220060 | Gastroretentive Formulations and Manufacturing Process Thereof - The present invention concerns gastroretentive formulation comprising an active substance granulated with a mixture of a weak gelling agent, a strong gelling agent, and a gas generating agent and process for manufacturing said formulation. | 09-11-2008 |
| 20080233188 | Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide - The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof. | 09-25-2008 |
| 20080241235 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20080241236 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20080241237 | Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family - The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions. | 10-02-2008 |
| 20080241238 | Controlled Release Coated Tablets Having Prolonged Gastric Retention - The present invention relates to a tablet composed of a core and a coating; said core is formed by two or more layers, wherein at least one of them contains an active agent ( | 10-02-2008 |
| 20080248110 | Pharmaceutical Compositions Useful in the Treatment of Pain - There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles. | 10-09-2008 |
| 20080248111 | Orodispersible Tablets of Bitter Active Principles - The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO″), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules. | 10-09-2008 |
| 20080274178 | Orally Disintegrating Tablet - By mixing an active ingredient, crystalline cellulose, an inorganic excipient, carmellose, and a lubricant at not more than 0.8% by weight per tablet, and compressing the mixture, or compressing the mixture by an external lubricating method, a palatable orally disintegrating tablet which maintains a tablet hardness and exhibits good disintegrating property can be obtained. | 11-06-2008 |
| 20080279934 | EXTENDED RELEASE FORMULATION FOR PRALNACASAN - This invention relates to a sustained release tablet comprising at least two layers, wherein at least one layer rapidly releases pralnacasan and the other layer releases pralnacasan in a delayed manner. This tablet is particularly suitable for the treatment of a condition such as autoimmune diseases, type I and type II diabetes, rheumatoid arthritis, osteoarthritis or psoriasis. | 11-13-2008 |
| 20080292696 | Enteric Sustained-Release Tablet Comprising Paroxetine - The present invention relates to an enteric, sustained-release tablet comprising paroxetine or a hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active substance, more particularly to a tablet prepared by coating a sustained-release tablet core containing paroxetine with an enteric polymer, wherein the interaction between the tablet core and the enteric coating layer is minimized to enable constant drug release without regard to the residence time of the tablet in the stomach. | 11-27-2008 |
| 20080292697 | Direct compression polymer tablet core - The present invention provides a tablet comprising a compressed tablet core which comprises at least about 80% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 80% by weight of an aliphatic amine polymer resin. The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: ( | 11-27-2008 |
| 20080292698 | PHARMACEUTICAL COMPOSITIONS OF ISOLATED ORTHORHOMBIC CRYSTALLINE 4-[6-ACETYL-3-[3-(4-ACETYL-3-HYDROXY-2-PROPYLPHENYLTHIO)PROPOXY]-2-PROPYLPHENOXY]BUTYRIC ACID AND METHODS OF USE - A pharmaceutical composition comprising a compound of formula (1) in polymorphic crystalline Form A: | 11-27-2008 |
| 20080299193 | Pharmaceutical composition comprising eszoplicone - The present invention relates to a stable pharmaceutical composition of eszopiclone with a defined particle size. | 12-04-2008 |
| 20080299194 | Pharmaceutical Formulation For Producing Rapidly Disintegrating Tablets - A pharmaceutical formulation in the form of agglomerates comprising
| 12-04-2008 |
| 20080305168 | In-Situ Melting and Gelling Tablet Composition For Oral Care - Disclosed herein is an oral care composition that provides pleasant cooling sensation and easy delivery of an oral care active ingredient. The tablet-type oral care composition of the present invention is prepared by compressing porous plastic granules at a pressure of 500 kg/cm2 or less and undergoes in situ melting and gelling by saliva or water in the buccal cavity, or by chewing. Upon direct administration of the composition to the buccal cavity, the composition undergoes melting and gelling by water or saliva, or by chewing action, and works to maintain oral health via gargling or mouth washing. Therefore, the formulation of the present invention advantageously reduces inconvenience of conventional liquid or ointment-like oral care products and also provides easy portability. | 12-11-2008 |
| 20080311193 | Sustained Release Formulation of Alprazolam - The present invention is directed towards the preparation of extended release Alprazolam formulation. The formulation thus obtained provides an efficient mode of delivery of Alprazolam in a continuous manner. | 12-18-2008 |
| 20080311194 | Dispersible Tablets Comprising Deferasirox - The present invention pertains to a dispersible tablet comprising (a) Compound I of the formula | 12-18-2008 |
| 20080311195 | BASIS PARTICLES, METHOD FOR MANUFACTURING THE SAME, AND ORALLY-DISINTEGRATING TABLET - A basis particle comprises a basic or acidic basis particle coated by a water-insoluble coating film, wherein the water-insoluble coating film contains a substance that is acidic with respect to the basic basis or basic with respect to the acidic basis. According to the basis particles (i.e., a main ingredient or an active drug)of the present invention, it is possible to temporarily adjust pH occurring in the immediate proximity of the basis particles by using a coating film, elution of the basis particles is suppressed and superior elution is exhibited without dependence on bodily pH. It is also possible to mask tastes such as the bitterness of the basis and it is possible to ingest drugs without sensing any bitterness. | 12-18-2008 |
| 20080311196 | All Day Rhinitic Condition Treatment Regimen - A therapeutic regimen is disclosed. The regimen includes a first pharmaceutical dosage form comprising a first therapeutically effective amount of a first antihistamine and an anticholinergic agent; and a second pharmaceutical dosage form comprising a therapeutically effective amount of a second antihistamine and an anticholinergic agent. The second antihistamine either has greater H | 12-18-2008 |
| 20080311197 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form. | 12-18-2008 |
| 20080317851 | IMMEDIATE RELEASE DOSAGE FORMS CONTAINING SOLID DRUG DISBURSIONS - High loading immediate release dosage forms containing at least 30 wt % of a solid drug dispersion, at least 5 wt % of a disintegrant and a porosigen are disclosed that exhibit excellent strength and aqueous solubility. | 12-25-2008 |
| 20080317852 | Pharmaceutical Combination - A pharmaceutical formulation for the treatment of HIV is provided. The formulation is a combination of a nucleoside reverse transcriptase inhibitor and a nucleotide reverse transcriptase inhibitor in which the combination has an increased stability over prior art combination therapies. The invention also provides a pharmaceutical product containing the formulation. | 12-25-2008 |
| 20080317853 | Mouth Dissolving Pharmaceutical Composition and Process for Preparing the Same - Disclosed herein is a orally disintegrating and/or dissolving oral pharmaceutical composition, comprising one or more active pharmaceutical ingredients, one or more fillers having particle size of 100 microns or above, a high and desirable amount of silicon dioxide, one or more disintegrating agents, optionally effervescent couple, wherein said composition has good organoleptic properties like desired mouth feel and fast oral disintegration time. | 12-25-2008 |
| 20080317854 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 12-25-2008 |
| 20090004267 | Dosage Form with Impeded Abuse - A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm. | 01-01-2009 |
| 20090004268 | Methods and Compositions for Treatment of an Interstitial Lung Disease - Provided herein are methods of treatment of an interstitial lung disease (ILD) by administering an endothelin antagonist, such as sitaxsentan or a pharmaceutically acceptable salt thereof. | 01-01-2009 |
| 20090011014 | Tablet Formulation for Sustained Drug-Release - Disclosed is a pharmaceutical sustained release tablet for oral administration of a drug which is made of a compressed blend of at least three dry powders including a powder of a drug, a powder of a sustained release matrix for the drug, and a powder of at least one electrolyte. The sustained release matrix consisting of an un-cross-linked high amylose starch wherein the high amylose is substituted by at least one organic substituent comprising at least one carboxyl group. This organic substituent is preferably a carboxyalkyl having 2 to 4 carbon atoms, its salt or mixture thereof. This tablet has the advantage of having an improved integrity. | 01-08-2009 |
| 20090011015 | METHOD FOR PROMOTING SLEEP - Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The supplemental composition may include at least an extract of Valerian Root, an extract of Willow Bark and Melatonin or a derivative thereof. The supplemental composition may be provided for consumption at least one time daily, e.g., prior to sleep. | 01-08-2009 |
| 20090011016 | Crush-Resistant Oxycodone Tablets Intended For Preventing Accidental Misuse And Unlawful Diversion - Water-insoluble matrix tablets based on oxycodone or one of its pharmaceutically acceptable salts and capable of prolonged release of oxycodone to the body, exhibiting a crush resistance of at least 4 MPa. | 01-08-2009 |
| 20090017114 | Tranexamic acid formulations with reduced adverse effects - Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced. | 01-15-2009 |
| 20090022794 | Topiramate Tablet Formulation - The invention provides pharmaceutical compositions comprising as active ingredient topiramate, which are suitable for manufacturing tablet formulations by direct compression. The compositions preferably comprise spray-dried granulated mannitol and provide tablets of desired friability and hardness. | 01-22-2009 |
| 20090022795 | Stable Pharmaceutical Formulation of an Acid Labile Compound and Process for Preparing the Same - The disclosed invention provides oral pharmaceutical formulations of an acid labile benzimidazole derivative comprising (a) a core comprising an acid labile benzimidazole derivative, (b) a seal coating layer, and (c) an enteric coating layer, wherein the core of the composition is devoid of any disintegrant. | 01-22-2009 |
| 20090022796 | Novel Substituted Benzimidazole Dosage Forms and Method of Using Same - The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor, including preparations of s-omeprazole, and at least one buffering agent. Also provided is a pharmaceutical composition comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules | 01-22-2009 |
| 20090041841 | CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS - Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. | 02-12-2009 |
| 20090053309 | ADHESIVE COMPOSITIONS FOR THE TREATMENT OF XEROSTOMIA - Compositions and methods for the treatment of xerostomia are disclosed herein. Methods for making the compositions are also disclosed herein. The compositions are designed for individuals having the physiologic ability to salivate but who do not salivate in sufficient quantity to satisfy their personal comfort level of oral hydration. The compositions are typically in the form of a film or tablet, preferably in the form of a sticker tablet, most preferably in the form of a double layer sticker tablet, where one layer contains a bioadhesive material and the second layer contains the sialogogic agent and the one or more lipids. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions contain a therapeutically effective amount of one or more sialogogic agents and one or more lipids for treating xerostomia and a pharmaceutically acceptable bioadhesive carrier. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The methods for treatment of xerostomia require placing the composition on the oral mucosa of a patient's mouth, preferably on the palate or the cheek. The composition will adhere to the mucosal surface and dissolve over a period of time. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to 8 hours following administration to the buccal or oral mucosa. | 02-26-2009 |
| 20090060995 | Dispersible sustained release pharmaceutical compositions - Disclosed herein are pharmaceutical compositions, in particular, dispersible compositions comprising sustained release granules of at least one active pharmaceutical ingredient and at least one release retard hydrophobic polymer formulated with super disintegrant and lubricant, to achieve dispersible and sustained release effect. | 03-05-2009 |
| 20090060996 | Formulations of Clopidogrel Bisulphate - This invention relates to pharmaceutical tablet formulations of clopidogrel bisulphate which include glyceryl dibehenate as lubricant. The tablets are found to be very stable and to exhibit suitable dissolution characteristics. | 03-05-2009 |
| 20090074861 | STABLE TABLET CONTAINING DROXIDOPA - A tablet containing droxidopa as an active ingredient in a proportion of 20-80 wt % relative to the total weight of the tablet, and characteristically containing at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose, and corn-derived starch is provided. In addition, a preparation containing corn-derived processed starch or polyvinyl alcohol as a binder and the like, which is a stable tablet containing droxidopa as an active ingredient, is provided. | 03-19-2009 |
| 20090074862 | LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME - The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. | 03-19-2009 |
| 20090074863 | Dosage Forms Containing A PPI, NSAID And A Buffer - Provided herein, are dosage forms comprising an NSAID, a buffer and a PPI, as well as methods of treating various maladies using the above dosage form. | 03-19-2009 |
| 20090081289 | PLANT AND A PROCESS FOR PRODUCTION OF TABLETS - The invention relates to a plant for production of tablets, a process for production of tablets and tablets as such. The plant comprises a mixing device producing a mixed liquid feed of active pharmaceutical ingredient and excipients. A spray dryer atomizes the mixed liquid feed and dried particles with a high flowability are produced. The dried particles are subsequently compressed to tablets in a tablet press. The invention possesses several advantages, including the possibility of using an auto mated rotary tablet press directly, thereby reducing the number of unit operations in the tablet production. | 03-26-2009 |
| 20090087486 | Foam Wafer Containing a Polyvinyl Alcohol-Polyethyleneglycol-Graft Copolymer - Sheet-like dosage forms dissolving or disintegrating in an aqueous medium for releasing at least one active substance in a body orifice or body cavity. The sheet-like dosage forms comprise a polymer matrix in the form of a solidified foam containing spaces or cavities, as well as at least one pharmaceutical or cosmetic active substance. The polymer of the polymer matrix is a polyvinyl alcohol-polyethylene glycol graft copolymer. Methods for producing such dosage forms are also provided. | 04-02-2009 |
| 20090092669 | STABLE IMATINIB COMPOSITIONS - Formulations containing imatinib, preferably imatinib mesylate, with high polymorphic stability and the processes for the preparation thereof are disclosed. | 04-09-2009 |
| 20090110725 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size not exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 04-30-2009 |
| 20090117183 | ORAL CONTRACEPTIVE CONTAINING A GESTAGEN AND AN ESTROGEN COMBINED WITH PHARMACEUTICALLY ACCEPTABLE AUXILIARY AGENTS AND/OR EXCIPIENTS, BUT NOT CONTAINING LACTOSE, AND METHOD OF MAKING SAME - The method produces a lactose-free oral contraceptive composition containing a combination of a gestagen and an estrogen together with one or more pharmaceutically acceptable auxiliary agents and/or excipients. The contraceptive composition is a tablet, powder, or capsule that contains the gestagen and estrogen, filler material such as microcrystalline cellulose and a binder such as hydroxypropylcellulose, but no lactose. Preferably the gestagen is dienogest, chlormadinone acetate, or levonorgestrel and the estrogen is ethinylestradiol, 17β-estradiol, or estradiol valerate. A method is provided for improving the prophylaxis of lactose intolerance in women taking oral contraceptives. The oral contraceptive preparations for a standard 28-day cycle or for long-term use contain at least 21 daily dose units of the gestagen and the estrogen in a low-dosage but without lactose and at most 7 daily dose units containing no active ingredient or a placebo. | 05-07-2009 |
| 20090136570 | Taste-Masked Tablets and Granules - Orally administered, taste-masked tablets and granules contain (a) a hydroxypyrimidinone carboxamide, a hydroxy-tetrahydropyridopyrimidinone carboxamide, or a related carboxamide compound, or a pharmaceutically acceptable salt thereof, (b) a taste-masking polymer, (c) a superdisintegrant, and optionally other excipients. The carboxamide compound is an HIV integrase inhibitor, and the tablets and granules are suitable for use in the inhibition of HIV integrase, the treatment or prophylaxis of HIV infection, and the treatment or prophylaxis or delay in the onset of AIDS. | 05-28-2009 |
| 20090136571 | PHARMACEUTICAL FORMULATIONS CONTAINING IRBESARTAN - The present invention relates to pharmaceutical compositions and formulations for the oral administration of Irbesartan, one of its pharmaceutically acceptable salts or its polymorphs, optionally combined with a diuretic and to a process for the manufacture of said composition. | 05-28-2009 |
| 20090142394 | Gastric Antacid - A novel particulate composite hydrotalcite which offers antacidic effect comparable to that of a particulate hydrotalcite so far used as a gastric antacid and, further, offers excellent stomach inner wall protection effect. A particulate composite hydrotalcite represented by the following formula (1), | 06-04-2009 |
| 20090142395 | DEFERASIROX PHARMACEUTICAL COMPOSITIONS - The present invention provides a process of preparing a high-load formulation of deferasirox with a sufficiently high dissolution rate and good bioavailability, which reduces the effect of the active material's physical characteristics on the chemical and physical properties of the final product. | 06-04-2009 |
| 20090148522 | HEATED ROLLER COMPACTION PROCESS FOR MAKING PHARMACEUTICAL COMPOSITIONS - A process for using a heated roller compactor to prepare melt granulated composition of a therapeutic compound, especially a poorly compressible and/or moisture sensitive therapeutic compound, with a granulation excipient. | 06-11-2009 |
| 20090162432 | Stable laquinimod preparations - The subject invention provides a pharmaceutical composition comprising N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-Chloro-6-(1-ethyl-N-methyl-2-oxoindoline-3-carboxamido)benzoic acid,1H,3H-spiro[5-chloro-1-methylquinoline-2,4-dione-3,3′-[1]ethylindolin-[2]-one], or 5-Chloro-N-ethyl-3-hydroxy-1-methyl-2,4-dioxo-N-phenyl-1,2,3,4-tetrahydro-quinoline-3-carboxamide. | 06-25-2009 |
| 20090169621 | Pharmaceutical excipient having improved compressibility - A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide. | 07-02-2009 |
| 20090175937 | Misuse Preventative, Controlled Release Formulation - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 07-09-2009 |
| 20090181083 | Porous tablets as carriers for liquid formulations - A novel tablet product that in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable liquid formulation e.g. carrying a therapeutically, prophylactically and/or diagnostically active substance. The novel loadable tablet product may be produced in large-scale batches and stored until use and each batch or sub-batch may be loaded with the same or different pharmaceutically acceptable liquid formulations and/or active substances. A loadable tablet according to the invention has a porosity of 30% v/v or more. The invention also provides tablets that have been loaded with such a liquid formulation as well as a method for the preparation thereof. | 07-16-2009 |
| 20090181084 | Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid - An oral fast-disintegrating tablet includes many tiny particles of slowly-releasable ascorbic acid, and a fast-disintegrating ingredient mixed with the many tiny particles that are dispersedly mixed with the fast-disintegrating ingredient. Each tiny particle is composed of a nucleus, an ascorbic layer and a release-control layer. The nucleus is coated with the ascorbic-acid layer and then with the releasing control layer to become a slowly-releasable particle. The tiny particles are mixed with the fast-disintegrating ingredient, which is composed of a mixture of ascorbic acid, water excipient, microcrystalline cellulose, a diluent agent, and disintegrant. So the tablet can be disintegrated swiftly in a mouth, and the tiny particles can enter the stomach and intestines with saliva to be slowly released, sustainingly absorbed by the organs. | 07-16-2009 |
| 20090196922 | BILAYER TABLET FOR PREVENTING CARDIOVASCULAR EVENTS - The present invention relates to a bilayer tablet which comprises a compartment containing a pharmaceutically acceptable simvastatin compound as its active ingredient; and at the same time a separate compartment containing a pharmaceutically acceptable lisinopril compound and a pharmaceutically acceptable folic acid compound as active ingredients, for the prevention of stroke in high-risk conditions or diseases. | 08-06-2009 |
| 20090208571 | Dosage form containing pantoprazole as active ingredient - Dosage forms for the oral administration of the magnesium salt of pantoprazole are described. | 08-20-2009 |
| 20090220594 | Tablet of Paracetamol Containing an Encapsulated Flavorant - A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink. | 09-03-2009 |
| 20090232889 | CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM - A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) | 09-17-2009 |
| 20090246276 | Pharmaceutical Compositions - The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fumarate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents across in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. | 10-01-2009 |
| 20090263480 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS PREPARED BY COACERVATION - There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. | 10-22-2009 |
| 20090269401 | Controlled Release Solid Preparation - Disclosed is a solid preparation which comprises at least one active ingredient and at least one dissolution-controlling base substance and can be formed by compression molding, wherein the dissolution-controlling base substance contains 5.0 to 99.9% by weight (inclusive) of a modified starch having a moisture retaining capacity of 400% or more and a gel indentation load of 200 g or more, containing a water-soluble ingredient in an amount of 40 to 95% by weight, having particles passing through a 75 μm-mesh sieve in the proportion of 90% by weight or more and particles passing through a 32 μm-mesh sieve in the proportion of 20% by weight or more, and having an average particle diameter of not smaller than 20 μm and smaller than 50 μm. | 10-29-2009 |
| 20090291136 | Multiple Unit Tablets - The present invention relates to multiple unit tablets comprising multiple units compacted together with at least two tablet filler-binders and optionally other pharmaceutically acceptable excipients, wherein at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 10% to 40%, and at least one of said tablet filler-binder is a tablet filler-binder having mean particle size-to-mean multiple unit size ratio from 1% to 10%. | 11-26-2009 |
| 20090297598 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 12-03-2009 |
| 20090297599 | PHARMACEUTICAL COMPOSITIONS CONTAINING ROSUVASTATIN CALCIUM - A pharmaceutical composition is disclosed containing amorphous rosuvastatin calcium and at least one of the following stabilizing agents: magnesium hydroxide, calcium acetate, calcium gluconate, calcium glycerophosphate, or aluminum hydroxide, together with at least one pharmaceutically acceptable excipient. | 12-03-2009 |
| 20090304791 | SOLID ORAL FORMS OF EBASTINE - The invention relates to compositions in the form of matrices consisting of solid ebastine dispersions in nonionic surfactants having a HLB of between 10 and 20 and a melting point of between 30° C. and 70° C. The invention also relates to solid oral pharmaceutical forms of ebastine containing said matrices, particularly tablets, and having good solubility and bioavailability properties and improved stability. | 12-10-2009 |
| 20090304792 | GRANULE AND ORALLY DISINTEGRATING TABLET COMPRISING OXYCODONE - The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen. | 12-10-2009 |
| 20090311320 | MULTILAYER ORALLY DISINTEGRATING TABLET - This invention pertains to an orally disintegrating multilayer tablet wherein it comprises at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and optionally a pore-forming agent. | 12-17-2009 |
| 20090311321 | ORAL DISINTEGRATING TABLET HAVING MASKED BITTER TASTE AND METHOD FOR PRODUCTION THEREOF - The present invention provides an orally disintegrating tablet containing mitiglinide calcium hydrate. The tablet has reduced bitterness and quickly disintegrates in the mouth, while exhibiting rapid dissolution in the digestive tract. The bitterness-masked orally disintegrating tablet comprises: (a) mitiglinide calcium hydrate; (b) microcrystalline cellulose; (c) at least one masking agent selected from the group consisting of aminoalkyl methacrylate copolymer E, polyvinylacetal diethylaminoacetate, an ethyl acrylate-methyl methacrylate copolymer, and ethyl cellulose; (d) a sugar or a sugar alcohol; and (e) at least one selected from corn starch and partially pregelatinized starch. | 12-17-2009 |
| 20090317462 | PEPTIDE PHARMACEUTICAL FOR ORAL DELIVERY - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 12-24-2009 |
| 20090317463 | COMPOSITION FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION - The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide. The present invention also relates to the use of SAMe, or salts thereof, in combination with inositol and/or derivatives thereof with the possible further addition of melatonine, St. John's Wort and/or lemon balm for the treatment of depressive states and/or panic syndromes. | 12-24-2009 |
| 20090324714 | DUAL ADHESIVE TECHNOLOGY - A dual adhesive layer dosage form for delivery of active agent to and across, the mucosa is disclosed. Particularly, bioadhesive tablets for administration at the vaginal mucosa are disclosed as having a central active layer sandwiched between two bioadhesive layers. | 12-31-2009 |
| 20100003319 | RALOXIFENE IMMEDIATE RELEASE TABLETS - The present invention relates generally to formulations containing raloxifene or pharmaceutical salts thereof, as the active pharmaceutical ingredient and a process for preparing the same. | 01-07-2010 |
| 20100015221 | ORALLY RAPID DISINTEGRATING TABLET PREPARATION COMPRISING FAT-SOLUBLE ACTIVE INGREDIENTS - The present invention provides an orally rapid disintegrating tablet preparation that contains a high dose of a fat-soluble active ingredient, that exhibits excellent disintegration characteristics in the oral cavity, and that can be produced by a dry tabletting method. The present invention also provides a method of producing an orally rapid disintegrating tablet preparation. The present invention discloses an orally rapid disintegrating tablet preparation that is obtained by tabletting a uniform mixture prepared by mixing saccharide alcohol, crystalline cellulose, and a lubricant with a granule that has been produced by the adsorption of a fat-soluble active ingredient on a porous material. | 01-21-2010 |
| 20100028426 | TIME-SPECIFIC DELAYED/PULSATILE RELEASE DOSAGE FORMS. - A time-specific delayed/pulsatile release dosage form which comprises:
| 02-04-2010 |
| 20100055179 | Composition of and Method for Preparing Orally Disintegrating Tablets Containing a High Dose of Pharmaceutically Active Ingredients - The present invention is directed to improved compositions and methods for preparing orally disintegrating tablets (ODTs). In one aspect of the present invention, the ODT further contains at least one active pharmaceutical ingredient (API). In another aspect of the present invention, the ODT contains a high load of at least one API. Specifically, the ODTs described in this invention containing a high load of API can accommodate up to about 70% w/w of active pharmaceutical ingredient in a unit dosage, while exhibiting the desirable attributes of fast disintegration time, acceptable hardness and friability for push through blister and bottle packages, and acceptable mouth feel. | 03-04-2010 |
| 20100055180 | Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof - An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API. | 03-04-2010 |
| 20100062062 | Stabilized Coating for Pharmaceutical Formulations - A process is described for preparing stabilized tablet formulations for temperature and moisture sensitive active drugs. Water soluble polyvinyl alcohol is processed with drugs such as angiotensin converting enzyme (ACE) inhibitors and compressed into solid form once excess water is removed. Low dose polyvinyl alcohol ramipril tablets prepared by this process are stable under conditions of high humidity and heat for periods of at least up to six months with less than 8% hydrolysis of the prodrug to the active metabolite diketopiperazine (DKP). | 03-11-2010 |
| 20100074948 | METHOD OF PRODUCING FAST DISSOLVING TABLETS - A method of producing a fast-melt tablet comprises the steps of forming a mixture of components, the mixture comprising at least one fast dissolving sugar alcohol, at least one disintegrant or osmotic agent, and at least one an active component, blending the mixture for a period of time, and directly compressing the blended mixture at a compression force of typically between 5 and 2O kN to form the fast-melt tablet. The process of the invention does not involve any granulation step, thereby making the process more energy efficient and cost effective. The fast dissolving sugar alcohol is selected from the group comprising: mannitol; sorbitol; erythritol; xylitol; lactose; dextrose; and sucrose, and comprises at least 50%, preferably at least 60%, and more preferably at least 70%, of the tablet (w/w). The active component is suitably provided in the form of microparticles or microcapsules having an average diameter of less than 125 microns. Also described are directly compressed fast dissolving type tablets obtainable by the process of the invention. The tablets typically are flat-faced. | 03-25-2010 |
| 20100092551 | SOLID PREPARATION COMPRISING ALOGLIPTIN AND PIOGLITAZONE - A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts:
| 04-15-2010 |
| 20100092552 | LOW DOSE CONTROLLED RELEASE TABLET - Low dose pharmaceuticals can be delivered for a prolonged period using a tablet-in-tablet design wherein the drug is contained in a controlled release matrix in the outer compression coating layer but not in the inner tablet core. | 04-15-2010 |
| 20100092553 | ANTI-MISUSE MICROPARTICULATE ORAL PHARMACEUTICAL FORM - The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. | 04-15-2010 |
| 20100098756 | ORAL DISINTEGRATING TABLET - An oral disintegrating tablet containing (1) D-mannitol, (2) an active ingredient, (3) one or more disintegrating agents selected from the group consisting of crospovidone and carmellose, and (4) one or more lubricants selected from the group consisting of sodium stearyl fumarate and sucrose esters of fatty acids. The oral disintegrating tablet of the present invention has some excellent properties of (1) allowing easy production in a common facility without necessitating a specialized pharmaceutical technique, (2) having an appropriate strength that does not breakdown in the process of distribution, (3) having a fast disintegrating ability in the oral cavity, and (4) also having excellent ingestion feel such as greatly reduced bitterness or gritty feel; therefore, the tablet can be suitably used as a dosage form that is suitable for aged individuals, children, and seriously ill patients. | 04-22-2010 |
| 20100104636 | Pharmaceutical Compound and Composition - A pharmaceutical composition comprising rosiglitazone or a pharmaceutically acceptable salt thereof wherein said rosiglitazone has a median particle size diameter of about 5 microns to about 20 microns. | 04-29-2010 |
| 20100104637 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 04-29-2010 |
| 20100112050 | Dosage Form For Insertion Into The Mouth - Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly anti-migraine agents to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. | 05-06-2010 |
| 20100124568 | PHARMACEUTICAL ARTICLES COATED WITH LUBRICIOUS COATINGS - The invention provides pills and tablets having lubricious coating deposited over the outer surface of the pills and the tablets. The coating comprises at least one hydrophilic polymer and at least one natural product, such as a natural polymer, a natural resin and/or a natural gum. | 05-20-2010 |
| 20100129444 | Novel Pharmaceutical Formulations of Modafinil - The present invention is related to compositions of modafinil, including compositions of modafinil and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof. | 05-27-2010 |
| 20100136111 | PHARMACEUTICAL COMPOSITIONS OF DICLOFENAC AND MISOPROSTOL - The present invention relates to pharmaceutical compositions of diclofenac or pharmaceutically acceptable salts thereof and misoprostol or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparations of such compositions. | 06-03-2010 |
| 20100136112 | Oxidizing composition including a gel layer - A composition that generates and releases a biocidal solution comprising at least chlorine dioxide is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a sustained release. | 06-03-2010 |
| 20100143465 | PHARMACEUTICAL COMPOSITION - A pharmaceutical tablet or tablet layer comprising the angiotensin II receptor antagonist telmisartan in amorphous form, a basic agent and sorbitol, characterized in that the sorbitol has a specific surface area of between 0.75-3.5 m | 06-10-2010 |
| 20100143466 | MODIFIED RELEASE IBUPROFEN DOSAGE FORM - The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose. | 06-10-2010 |
| 20100151017 | Oral Preparation With Controlled Release - A pharmaceutical pellet is disclosed, comprising a spherical core containing active ingredient with a smooth surface and a coating on the core which controls the release of the active ingredient in a pH-independent manner. With such a pellet the release of the active ingredient can follow a profile with a lag phase of 60 minutes to 840 minutes, a proportion of 5 wt. % or less of the active ingredient being released during the lag phase. The active ingredient can furthermore be released from the pellet with a profile such that after the lag phase the release of the active ingredient amounts to between 3 and 25 wt. % per hour. | 06-17-2010 |
| 20100151018 | SUSTAINED-RELEASE LEVETIRACETAM COMPOSITION AND PREPARATION PROCESS - A subject of the present invention is a novel formulation of levetiracetam making it possible to obtain a solid pharmaceutical composition, particularly intended for oral administration, for the sustained release of levetiracetam. A subject of the invention is also a process for the preparation of such a pharmaceutical composition. | 06-17-2010 |
| 20100151019 | SOLID COMPOSITION FOR CONTROLLED RELEASE OF IONIZABLE ACTIVE AGENTS WITH POOR AQUEOUS SOLUBILITY AT LOW pH AND METHODS OF USE THEREOF - A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37° C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration. | 06-17-2010 |
| 20100151020 | DRUG DELIVERY SYSTEM FOR ZERO ORDER, ZERO ORDER BIPHASIC, ASCENDING OR DESCENDING DRUG DELIVERY OF METHYLPHENIDATE - The invention is directed to a drug delivery device for controlled release of a drug, such as methylphenidate hydrochloride. The drug deliver device has a drug core, having a plug embedded therein, and at least a first coating that at least partially surrounds the core. The plug may be hollow or solid, and swells upon absorption of water, bursting through the first coating. The drag delivery device enables zero-order drug release profiles as well as more complicated release profiles to be obtained. | 06-17-2010 |
| 20100151021 | Compositions Comprising Melperone - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing melperone and/or a pharmaceutically acceptable salt, solvate, or ester thereof; a layer of alkaline buffer, and a controlled-release coating. The present invention is also directed to pharmaceutical dosage forms, including orally disintegrating tablets, conventional tablets, and capsules, and methods for their preparation. | 06-17-2010 |
| 20100159003 | PROCESS FOR THE PREPARATION OF A MEDICAMENT COMPRISING VARDENAFIL HYDROCHLORIDE TRIHYDRATE - The present invention relates to a process for the preparation of a medicament containing vardenafil hydrochloride trihydrate in solid form, in which vardenafil hydrochloride trihydrate is processed with suitable pharmaceutical auxiliaries at a temperature of from approx. 20° C. to approx. 45° C. | 06-24-2010 |
| 20100166857 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF MANUFACTURING SAME - The invention provides solid dispersions of at least one insoluble active pharmaceutical ingredient, pharmaceutical dosage forms comprising the solid dispersions, and methods of manufacturing same. In an embodiment, a solid dispersion of the present invention includes a plurality of coated particles comprising inert particles with a coating, wherein the coating comprises an insoluble active pharmaceutical ingredient dispersed in a hydrophilic polymer, and wherein the inert particles comprise nonpareils; and a plurality of granules comprising an insoluble active pharmaceutical ingredient with at least one pharmaceutically acceptable excipient. In an embodiment, the insoluble active pharmaceutical ingredient in the coating and the insoluble active pharmaceutical ingredient of the granules are the same type. A solid dispersion of the present invention may optionally be encapsulated in capsules or compressed into a tablet. Also disclosed are methods of making solid dispersions and methods of reducing plasma triglyceride and increasing high-density lipoprotein employing the solid dispersion. | 07-01-2010 |
| 20100172979 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating. | 07-08-2010 |
| 20100172980 | Tablet Containing Coated Particles of Cetirizine, Pseudoephedrine, and/or Naproxen - In one aspect, the present invention features a tablet including a first drug layer and a second drug layer, wherein: (i) the first drug layer includes first drug particles including naproxen and third drug particles including cetirizine, where the first drug particles and/or the third drug particles are coated with an immediate release coating; and (ii) the second drug layer including pseudoephedrine, wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours. | 07-08-2010 |
| 20100178338 | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING ATORVASTATIN - This invention relates to stabilized pharmaceutical compositions comprising atorvastatin or pharmaceutically acceptable salts thereof, and processes for the preparation of the same. | 07-15-2010 |
| 20100178339 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-15-2010 |
| 20100178340 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-15-2010 |
| 20100183715 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-22-2010 |
| 20100183716 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 07-22-2010 |
| 20100183717 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating. | 07-22-2010 |
| 20100189783 | RELATING TO ANTI-HIV TABLET FORMULATIONS - An anti-HIV tablet formulation comprising a core containing 0.1 to 1.5% by weight (w/w) of colloidal silicon dioxide and 0.4 to 0.9% by weight (w/w) of a lubricant, the balance of the core comprising darunavir, a disintegrant and a filler comprising a spray-dried mixture of microcrystalline cellulose and colloidal silicon dioxide, the core being optionally coated with a film coating. | 07-29-2010 |
| 20100189784 | Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals - The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. | 07-29-2010 |
| 20100196471 | NOVEL TABLET DOSAGE FORM - The present invention relates to novel tablet dosage forms and methods of preparing these forms, which can be used for different classes of pharmaceutical active ingredients posing stability issues in a single unit system. The dosage form includes a first layer, which includes a tablet of one or more active pharmaceutical ingredients, which is inlayed in the first layer along with other pharmaceutically acceptable excipients, and a second layer that includes one or more active pharmaceutical ingredients optionally with other pharmaceutically acceptable excipients. | 08-05-2010 |
| 20100196472 | MODIFIED RELEASE COMPOSITIONS OF MILNACIPRAN - A milnacipran formulation that provides delayed and extended release of milnacipran has been developed. The formulation comprises milnacipran or a salt thereof; an extended release excipient, and a delayed release excipient. The formulation provides, upon administration to a human subject, a T | 08-05-2010 |
| 20100203125 | SYNERGISTIC ANTIBACTERIAL FORMULATION AND A METHOD OF MAKING THE SAME - An antibiotic formulation including penicillinase resistant penicillin, cefixime trihydrate, | 08-12-2010 |
| 20100203126 | MULTILAYERED VITAMIN COMPLEX TABLET CONTAINING UBIDECARENONE - The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various vitamins. | 08-12-2010 |
| 20100203127 | LARGE DOSE RIBAVIRIN FORMULATIONS - The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin. | 08-12-2010 |
| 20100215740 | TASTE-MASKED ORALLY DISINTEGRATING TABLETS OF MEMANTINE HYDROCHLORIDE - The present invention relates to a solid pharmaceutical composition comprising memantine, which dissolves or disintegrates in the oral cavity preferably within about 60 seconds. The present invention further discloses orally disintegrating tablets of taste-masked memantine of optimal mechanical strength comprising memantine along with a taste-masking agent and pharmaceutically acceptable excipients. | 08-26-2010 |
| 20100215741 | PHARMACEUTICAL COMPOUNDS - Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): | 08-26-2010 |
| 20100215742 | DRUG ACTIVE IN NEUROPATHIC PAIN - The present invention relates to a compound of formula (I): in which: R is a linear or branched alkyl group containing between 1 and 3 carbon atoms, Y is CH or N, and p is an integer between 0 and 3 and preferably 0 and 1, and salts thereof, either acid-addition salts with a pharmaceutically acceptable organic or mineral acid, or base-addition salts with a pharmaceutically acceptable organic or mineral base. The invention also relates to a process for preparing the compound of formula (I), and to a pharmaceutical composition comprising it. The invention also relates to the use of an indazole for preparing a pharmaceutical composition that is active in the treatment of neuropathic pain. | 08-26-2010 |
| 20100221333 | Pellets Comprising a Core With a Water-Soluble Carrier - A pellet with a length/width ratio of less than about 1.4 is provided which comprises a core which comprises a water-soluble carrier and an active ingredient distributed homogeneously therein. The pellet disintegrates, with visually ascertainable loss of the pellet structure, into smaller fragments when the following test is carried out: (a) 200 to 800 mg of pellets are placed into a Petri dish with 0.5 ml of demineralized water. (b) The Petri dish is immediately afterwards fixed to the measuring cylinder holder of a stamping volumeter. (c) After 10 seconds, 30 stamping movements are carried out. (d) Immediately afterwards, the pellets are photographed. | 09-02-2010 |
| 20100221334 | COMPOSITIONS INCLUDING LEUKOTRIENE ANTAGONISTS AND NSAIDS AND METHODS OF USING THE SAME - Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs (NSAIDs) and modified NSAIDs and leukotriene antagonists and methods for using such pharmaceutical compositions are provided herein. In a preffered embodiment naproxene 2-(methanesulfonyl)-ethyl ester is used in combination with Zileuton. | 09-02-2010 |
| 20100226979 | Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate - Disclosed herein a taste masked pharmaceutical composition suitable for oral solid dosage form comprising adsorbate of unpleasant or objectionable tasting active pharmaceutical agents and water insoluble polymer, wherein said active is first blended with an adsorbent such as magnesium aluminium silicate to achieve partially or significantly taste masking of said active and further granulated the resultant blend with water insoluble polymer to strengthen the taste masking without affecting the release of said active. | 09-09-2010 |
| 20100226980 | NOVEL TABLET BASED ON S-ADENOSYL-METHIONINE - A subject of the invention is a tablet for pharmaceutical use, particularly for veterinary use, particularly suitable for the chronic treatment of hepatic insufficiency, comprising at least one S-Adenosyl-Methionine salt. Said tablet has the advantage of being divisible and being capable of including an appetizing agent. | 09-09-2010 |
| 20100226981 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A GABAPENTIN PRODRUG - Sustained release oral dosage forms with a high loading of a gabapentin prodrug are disclosed. | 09-09-2010 |
| 20100233258 | TABLET HAVING CONCAVITY WITH ACTIVE INGREDIENT DISPOSED THEREIN AND MANUFACTURING METHOD THEREOF - The present invention provides a method of manufacturing tablets. An example of the method involves preparing a placebo blend containing only excipients. This placebo blend is compressed into tablets having concavities such as pinholes or indentations. Separately, a dispersion containing an active pharmaceutical ingredient, a drug, or a drug substance is prepared. A predetermined amount of this dispersion is placed into those concavities, and the tablets are dried. In this method, an active ingredient is handled in the form of a dispersion rather than as a solid. In addition, once the tablets are dried, the active ingredient is trapped inside the concavities and remains unexposed to external physical friction. As a result, human contact with powders or dust of active ingredient during the manufacturing and shipping processes may be minimized in a cost-effective manner. The present invention is also directed to the tablets prepared by this method. | 09-16-2010 |
| 20100247642 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR - A dosage form is provided for an anti-diabetic DPP-IV inhibitor of formula (I) as its tartarate salt, wherein the purity of the active pharmaceutical ingredient is maintained over a prolonged storage period under conditions similar to those likely encountered in home storage of the medication by a diabetic patient. A formulation free of calcium salts such as calcium phosphate, but including microcrystalline cellulose, copovidone, crospovidone, colloidal silicon dioxide, and magnesium stearate, when compacted into a tablet with the active pharmaceutical ingredient, was shown to be stable for at least six months at 40° C. and 75% relative humidity. Methods for preparation of the dosage form are also provided. | 09-30-2010 |
| 20100247643 | Oral formulations - A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed. | 09-30-2010 |
| 20100247644 | ADHESIVE COMPOSITIONS FOR THE TREATMENT OF XEROSTOMIA - Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa. | 09-30-2010 |
| 20100255090 | Controlled release matrix pharmaceutical dosage formulation - A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer | 10-07-2010 |
| 20100255091 | ORAL FAST DISINTEGRATING TABLETS - The present invention refers to an orally fast disintegrable pharmaceutically acceptable multiple units tablet dosage form comprising a) tablet excipients comprising a disintegrant and b) individual units wherein each individual unit comprises:
| 10-07-2010 |
| 20100255092 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ACCELERATED CONTROLLED ACTIVE SUBSTANCE RELEASE - The present invention relates to pharmaceutical or nutraceutical preparations comprising a) a core containing a pharmaceutically or nutraceutically active substance; and b) a controlling layer surrounding the core comprising i) 55 to 92% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of 80 to 98% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from Ci to C4 alkyl esters of (meth)acrylic acid and 2 to 20% by weight based on the weight of the (meth)acrylic copolymer of structural units derived from (meth)acrylate monomers with a quaternary ammonium group in the alkyl radical; and ii) 8 to 45% by weight based on the total weight of (meth)acrylic copolymers present in the layer of one or a mixture of a plurality of (meth)acrylate copolymers composed of more than 5 to 59% by weight based on the weight of the copolymer of structural units derived from acrylic acid or methacrylic acid, and to tablets and capsules containing same. | 10-07-2010 |
| 20100272800 | ORALLY DISINTEGRATING OLANZAPINE TABLET - According to the present invention an orally disintegrating olanzapine tablet comprising magnesium stearate and sodium stearyl fumarate and one or more phramaceutically acceptable excipient in which the total weight of magnesium stearate and sodium stearyl fumarate is about 0.1 to 5% by weight of the total tablet and wherein the tablet disintegrates within up to 90 seconds in oral cavity is provided. | 10-28-2010 |
| 20100272801 | PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND VALSARTAN - A single layer pharmaceutical composition comprising active agent(s) amlodipine or a pharmaceutically acceptable salt thereof and valsartan or a pharmaceutically acceptable salt thereof wherein the composition exhibits bioequivalence to the commercially available bilayer tablet dosage form comprising amlodipine besylate and valsartan; when administered to human subject, under the bioequivalence parameters of a 90% Confidence Interval for AUC which is between 80% and 125%, and a 90% Confidence Interval for Cmax, which is between 80% and 125%. | 10-28-2010 |
| 20100278912 | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition - The present invention provides a pharmaceutical composition for use in a dosage form for oral administration to a patient. The composition expands upon contact with gastric fluid and promotes retention of the dosage form in the patient's stomach for a prolonged period of time. The present invention further provides pharmaceutical dosage forms containing an active ingredient, and the pharmaceutical composition. The forms are adapted for immediate or controlled release of the active ingredient. The dosage forms may be used advantageously in the treatment of Parkinson's disease with levodopa and hyperactivity and attention deficit disorder with methylphenidate. | 11-04-2010 |
| 20100278913 | CHEWABLE TABLET - An excipient base for a chewable tablet comprising xylitol, sucralose and microcrystalline cellulose. The excipient base provides for an improved taste, stabilization, and mouthfeel qualities for the chewable tablet, as well as a greater likelihood for dosage compliance and use. The excipient base also enables the tablet to be directly compressible, free flowing and non-tacky, thus avoiding wet granulation techniques that can degrade the product and add to the cost of the manufacturing process. The excipient base also allows for the production of a chewable tablet that is suitable for administration to persons and animals having diabetes or hypoglycemia, and does not promote tooth decay or dental caries. | 11-04-2010 |
| 20100285123 | Controlled Release Dosage Formulation of Duloxetine - The preset invention provides a controlled release dosage form of duloxetine comprising a homogenous core comprised of duloxetine or its pharmaceutically acceptable salts, pharmaceutically acceptable polymeric carrier, solubility enhancer, a hydrophobic component, a hydrodynamic diffusion enhancer, a viscolyzing agent and pharmaceutically acceptable excipients; a entering coat on said core and a barrier layer between said core and the enteric coat. | 11-11-2010 |
| 20100285124 | TETRAHYDROCYCLOPENTA[C]ACRIDINE DERIVATIVES AS KINASE INHIBITORS AND BIOLOGICAL - The invention relates to kinase inhibitors of the formula (I) in which —R | 11-11-2010 |
| 20100291207 | PHARMACEUTICAL FORMULATION COMPRISING EZETIMIBE - The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 μm to 35 μm and d(0.5) of 3 μm to 20 μm, as well as methods for preparing said formulations. | 11-18-2010 |
| 20100297226 | MULTIPLE UNIT PHARMACEUTICAL FORMULATION - An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer. | 11-25-2010 |
| 20100297227 | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ACTIVE AGENT AND A BINDER, WHICH SWELLS IN AN ACIDIC MEDIA - The invention relates to a pharmaceutical composition, which comprises at least one active agent and which further comprises a binder and/or a retarding agent, wherein the binder swells in an acidic medium, and the retarding agent retards the release of the active agent in an acidic or alkaline medium. | 11-25-2010 |
| 20100310651 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer. | 12-09-2010 |
| 20100310652 | COATED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM - An extended release pharmaceutical composition comprising levetiracetam. A coated extended release pharmaceutical composition comprising levetiracetam wherein the core is coated with a rate controlling composition. | 12-09-2010 |
| 20100316708 | Novel Pharmaceutical Formulation Containing A Biguanide and a Thiazolidinedione Derivative - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 12-16-2010 |
| 20100323007 | A POLYAMIDE RATE-MODULATED MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to a polyamide rate-modulated monolithic drug delivery system comprising at least one active compound and a biodegradable and biocompatible polyamide polymer. The polymer is selected for delivering, in use, the active compound, within a predetermined time frame depending on the biodegradable properties of the polymer, to a target organism or organisms. In one embodiment of the invention the polymer is modified by salting-out or crosslinking the polymeric material to achieve the desired biodegradability characteristics and, consequently, to control the release of the active compound. | 12-23-2010 |
| 20100323008 | SOLID DOSAGE FORM COMPRISING A FIBRATE - The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations. | 12-23-2010 |
| 20100323009 | Tablet composition for the in-situ generation of chlorine dioxide for use in antimicrobial applications - A solid composition in the form of a tablet that generates and releases a biocidal solution comprising at least chlorine dioxide with an enhanced weight percent yield is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide comprising a chlorite donor that is coated with a gel-forming material that slows the rate of dissolution of the high solubility chlorite donor, a free halogen donor, and an acid source, resulting in an unexpectedly high weight percent yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging and significantly increase the utility of the composition. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a controlled and sustained release. | 12-23-2010 |
| 20100323010 | FORMULATION AND PROCESS FOR DRUG LOADED CORES - The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. | 12-23-2010 |
| 20100323011 | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR - Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof. | 12-23-2010 |
| 20100330175 | CROSS-LINKED POLYALLYLAMINE TABLET CORE - A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and/or a lubricant, and further tableting the resulting blend to form tablets and tablet cores. | 12-30-2010 |
| 20100330176 | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity - The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity. | 12-30-2010 |
| 20100330177 | PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR - Disclosed are pharmaceutical compositions comprising fixed-dose combinations of an extended-release form of metformin, or a pharmaceutically acceptable salt thereof, coated with an immediate-release form of the DPP-4 inhibitor sitagliptin, or a pharmaceutically acceptable salt thereof. | 12-30-2010 |
| 20110002988 | ORALLY RAPIDLY DISINTEGRATING TABLET COMPRISING IMIDAFENACIN - Provided herein is an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. | 01-06-2011 |
| 20110008429 | Anti-Retroviral Combination - A pharmaceutical composition comprising a solid unit dosage form comprising:
| 01-13-2011 |
| 20110008430 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-13-2011 |
| 20110014283 | NOVEL DOSAGE FORM - The present invention relates to a novel dosage form, to a process for preparing the dosage form and to the use of the dosage form in the treatment of neurological and psychiatric disorders. | 01-20-2011 |
| 20110014284 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising a SGLT-2 inhibitor, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders. | 01-20-2011 |
| 20110020445 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM - Extended release pharmaceutical compositions of levetiracetam or pharmaceutically acceptable salts thereof in the form of a tablet comprising glyceryl behenate and a polymethacrylate polymer with at least one pharmaceutically acceptable excipient. | 01-27-2011 |
| 20110020446 | METHODS AND FORMULATIONS FOR MAKING PHARMACEUTICAL COMPOSITIONS CONTAINING BUPROPION - Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet. | 01-27-2011 |
| 20110027358 | VALSARTAN TABLET FORMULATIONS - The present invention relates to a pharmaceutical tablet composition comprising an effective amount of valsartan. The tablet is prepared by wet granulation and exhibits satisfactory disintegration properties. The invention also relates to a process for preparation of a pharmaceutical tablet composition comprising an effective amount of valsartan wherein the process involves a wet granulation step. | 02-03-2011 |
| 20110027359 | Novel Pharmaceutical Compositions Comprising Levetiracetam - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 02-03-2011 |
| 20110027360 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS - Compositions and methods to improve the pharmacokinetic profile of S-Adenosylmethionine (SAMe) are provided, as are methods of treating various disorders using SAMe formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous SAMe. The method also includes the step of orally administering compositions of the invention to the subject once per day after overnight fast; that is prior to food intake in the morning. | 02-03-2011 |
| 20110027361 | EXTENDED RELEASE DOSAGE FORM OF PALIPERIDONE - The present invention relates to an extended release solid oral pharmaceutical composition comprising Paliperidone or its pharmaceutically acceptable salts and process for preparing the same. | 02-03-2011 |
| 20110027362 | TABLET HAVING IMPROVED ELUTION PROPERTIES - The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. | 02-03-2011 |
| 20110033532 | AQUEOUS POLYMER DISPERSION BASED ON N,N-DIETHYLAMINOETHYL METHACRYLATE, ITS PREPARATION AND USE - The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof. | 02-10-2011 |
| 20110033533 | GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS - The present invention relates to a roller compacted solid oral dosage form comprising a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, wherein the active ingredient is present in an amount of more than 38% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form. | 02-10-2011 |
| 20110033534 | CONTROLLED RELEASE TAMSULOSIN HYDROCHLORIDE TABLETS AND A PROCESS OF MAKING THEM - The present invention relates to a controlled release preparation of tamsulosin hydrochloride comprising hydroxypropylcellulose and polyethylene oxide, and the process for making such pharmaceutical composition. | 02-10-2011 |
| 20110033535 | PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF - The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition. | 02-10-2011 |
| 20110033536 | 24-HOUR SUSTAINED-RELEASE METOCLOPRAMIDE - The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 30 mg drug substance 5 tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water, forming a gel coat which controls drug substance release. The water inside the matrix dissolves the drug substance and this is diffused outside through the gel coat. The hydrophobic polymer shows plastic deformation properties under compression, tending to surround the drug substance particles reducing the pore quantity and dimensions in the matrix structure, delaying as a consequence the drug substance release. The hydrophilic component is part of the gel coating structure providing support thereto. Drug substance is the metoclopramide hydrochloride or a pharmaceutically acceptable salt thereof. | 02-10-2011 |
| 20110038928 | ORALLY DISINTEGRATING TABLETS OF ZOLMITRIPTAN - The present invention is directed to a novel rapidly dissolvable pharmaceutical composition comprising zolmitriptan or pharmaceutically acceptable salts or esters thereof and least one direct compression filler. The pharmaceutical compositions of the present invention can advantageously be prepared in a solid dosage form, e.g. a tablet, utilizing directly compressible ingredients. | 02-17-2011 |
| 20110045068 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL ADMINISTRATION OF PPI - The present invention relates to pharmaceutical formulations comprising a layer of compressed granules to facilitate the administration of oral PPI. | 02-24-2011 |
| 20110052684 | PHARMACEUTICAL COMPOSITION - The present invention relates to a pharmaceutical composition comprising a tablet core comprising a combination of actives selected from the group consisting of bupropion hydrochloride and escitalopram oxalate, bupropion hydrobromide and citalopram hydrochloride, bupropion hydrobromide and escitalopram oxalate, and bupropion hydrobromide and quetiapine fu-marate, and at least one pharmaceutically acceptable excipient, and a control-releasing coat surrounding the tablet core, wherein said composition surprisingly provides for a synchronous release of the combination of active agents in-vitro. The once-daily pharmaceutical composition surprisingly also provides for enhanced absorption of bupropion hydrobromide when administered to a subject in need of such administration. | 03-03-2011 |
| 20110059171 | ORAL GALENIC FORMULATION INCLUDING KETOROLAC AND B-COMPLEX VITAMINS, IN WHICH VITAMIN B6 IS IN AN OUTER LAYER SEPARATED FROM THE REST OF THE ACTIVE PRINCIPLES - The invention relates to a solid oral pharmaceutical composition combining ketorolac and B-complex consisting of inter alia thiamin, pyridoxine and cyanocobalamin (vitamins B1, B6 and B12 respectively) and/or the pharmaceutically acceptable salts thereof, as well as pharmaceutically acceptable excipients and/or vehicles. The invention also relates to the method for producing the composition and to the use of said composition having a synergistic therapeutic activity, indicated for the treatment of moderate to severe pain or neuralgias in different locations. | 03-10-2011 |
| 20110064806 | SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME - The invention provides solid compositions comprising (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid (OC-1) or a salt thereof and methods of making and using those compositions. The invention also provides the monohydrochloride salt of (S)-3-(4′-Cyano-biphenyl-4-yl)-2-{[(3S,7S)-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-1-methyl-2-oxo-6-((S)-1-phenyl-propyl)-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl]-amino}-propionic acid. | 03-17-2011 |
| 20110070303 | NOVEL DOSAGE FORMULATION - The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I | 03-24-2011 |
| 20110076326 | MODIFIED PROTEIN EXCIPIENT FOR DELAYED-RELEASE TABLET - The present invention relates to delayed release oral formulations comprising active ingredients and modified proteins used as excipients. The proteins have chemical modifications such as succmylation, deammation, glytarylation or phosphorylation which decrease the isoelectric point of the protein compared to the protein's native isoelectric point and enhance protem-protem interactions, thereby reducing solubility and swelling, and delaying release of the active ingredient when the formulation is ingested orally. Particularly, the invention relates to tablets that comprise an excipient of chemically-modified food proteins such as soy proteins or -lactoglobulm useful for delaying release of an active ingredient such as a pharmaceutical drug or a probiotic. | 03-31-2011 |
| 20110081415 | COATING APPARATUS - A sugar-coated agent that includes a core, a film layer that mainly includes a film component, the outer surface of the core being coated with the film layer, a sugar coating layer that mainly includes a sugar coating component, the outside of the film layer being coated with the sugar coating layer, and a middle layer that includes a film component and a sugar coating component and is provided between the film layer and the sugar coating layer, wherein within the middle layer, the concentration of the sugar coating component at the interface between the middle layer and the sugar coating layer is higher than the concentration of the sugar coating component at the interface between the middle layer and the film layer. | 04-07-2011 |
| 20110086096 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients:
| 04-14-2011 |
| 20110091546 | COMPOSITION FOR RAPID DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides rapid disintegrating tablets in oral cavity having a shortened disintegration time in oral cavity as well as a sufficient hardness with compared to rapid disintegrating tablets of the prior art. | 04-21-2011 |
| 20110091547 | Pharmaceutical Compositions Comprising Brivaracetam - The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation. | 04-21-2011 |
| 20110104271 | Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients - Compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. The recompactibility performance of such compositions is improved through the use of calcium phosphate having a relatively small particle size, e.g., a median particle size of not more than about 20 microns or not more than about 10 microns. | 05-05-2011 |
| 20110104272 | GASTRIC RETENTIVE EXTENDED-RELEASE DOSAGE FORMS COMPRISING COMBINATIONS OF ACETAMINOPHEN AND PHENYLEPHRINE - Compositions and methods for the treatment of a mammal suffering from pain and from nasal congestion or ophthalmic disorders are described. More specifically, a dosage form designed for release of acetaminophen and phenylephrine is described, wherein the dosage form provides delivery of the drugs to the upper gastrointestinal tract (“GI”) of a mammal for an extended period of time. | 05-05-2011 |
| 20110104273 | GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF PHENYLEPHRINE - Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described. | 05-05-2011 |
| 20110111025 | High Drug Load Formulations and Dosage Forms - The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient. | 05-12-2011 |
| 20110111026 | HUMIDITY-RESISTANT DRUG FORMULATIONS AND METHODS OF PREPARATION THEREOF - The invention relates to a pharmaceutical composition of a humidity-sensitive core comprising an active ingredient or pharmaceutically acceptable salt thereof; a coating over the core, the coating containing a cationic polymer; and an additional coating over the cationic polymer-containing coating, with the additional coating including an acidifying agent. Also, methods for preparing such compositions wherein a cationic polymer containing coating is applied over a humidity-sensitive core that contains the active ingredient or pharmaceutically acceptable salt thereof; and then an additional coating is applied over the cationic polymer containing coating. | 05-12-2011 |
| 20110117193 | ANTIRETROVIRAL DRUG FORMULATIONS FOR TREATMENT OF CHILDREN EXPOSED TO HIV/AIDS - The present disclosure provides fast disintegrating formulations for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in patients such as neonatal, perinatal and pediatric children. Neonatal and perinatal formulations provide for the prevention or reduction of incidence of mother to child transmission of HIV. Also provided are formulations and methods for treating pediatric children having HIV/AIDS. The orally administered fast disintegrating formulations are in granule and tablet form and are specially formulation for children to increase adherence to treatment protocols. | 05-19-2011 |
| 20110117194 | PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER - The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time. | 05-19-2011 |
| 20110123617 | CLIOQUINOL FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The present invention relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In particular, the present invention relates to compositions and methods for treating the hematological malignancies acute myeloid leukemia (AML) and multiple myeloma (MM) using clioquinol. | 05-26-2011 |
| 20110135722 | PHARMACEUTICAL FORMULATION COMPRISING A PROTON PUMP INHIBITOR AND ANTACIDS - The present invention deals with a multiparticulate tablet, which disintegrates in the mouth containing: i) a proton pomp inhibiting agent, in particular of the benzimidazole type, in the form of enteric coated microgranules, which enteric coated granules are overcoated with at least one barrier coating, such as for instance a methacrylic copolymer-based protective film; ii) at least one antacid in the form of granules, for instance based on CaCO | 06-09-2011 |
| 20110135723 | PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN - The present invention provides pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing. The present invention further relates to pharmaceutical composition comprising pregabalin that is useful for once daily oral dosing comprising pregabalin and on or more water insoluble components. The present invention preferably relates to a gastro-retentive tablet comprising pregabalin and one or more water insoluble component wherein water insoluble component preferably comprises of combination of ethylcellulose and hydrogenated castor oil. | 06-09-2011 |
| 20110135724 | Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting - This invention is related to a pharmaceutical composition in the patient-friendly orally disintegrating tablet form comprising a weakly basic, selective serotonin 5-HT | 06-09-2011 |
| 20110142928 | PROCESS FOR THE PRODUCTION OF CALCIUM COMPOSITIONS IN A CONTINUOUS FLUID BED - The present invention discloses a process for producing a particulate material comprising a calcium-containing compound, the process comprises granulating and/or coating a powder mixture, which comprises the calcium-containing compound together with one or more pharmaceutically acceptable excipients in a continuous fluid bed apparatus. | 06-16-2011 |
| 20110142929 | SOLID PHARMACEUTICAL FORMULATIONS COMPRISING BIBW 2992 - The present invention relates to a pharmaceutical dosage form containing the active substance BIBW 2992 as the dimaleate salt, providing an immediate release profile of the active substance, further, the invention relates to compacted intermediates comprising BIBW 2992 dimaleate salt (BIBW 2992 MA | 06-16-2011 |
| 20110142930 | Pharmaceutical Compositions of Atorvastatin - A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition. | 06-16-2011 |
| 20110142931 | SOFT TABLET CONTAINING DEXTROSE MONOHYDRATE - The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising directly compressible dextrose monohydrate and sucralose, said tablet being substantially fat free and said matrix being substantially free of non-saccharide, water soluble polymeric binders. | 06-16-2011 |
| 20110150994 | Modified Release Formulation - The invention is directed to the use of an extended release tablet formulation for pramipexole. | 06-23-2011 |
| 20110159092 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING LINEZOLID AND PROCESS FOR PREPARING THE SAME - The present invention provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid or pharmaceutically acceptable salt, derivative, prodrug, metabolite and polymorph thereof and one or more pharmaceutically acceptable excipients and a process of preparing the same. The present invention further provides a method of treating bacterial infections in a mammal comprising administering an extended release, pharmaceutical composition suitable for once daily dosing comprising Linezolid capable of maintaining T>MIC for at least 24 hours. The present invention further provides an extended release pharmaceutical composition suitable for once daily dosing comprising Linezolid so that upon oral administration the maximum concentrations (C | 06-30-2011 |
| 20110165235 | DIRECTLY PRESSED ALISKIREN TABLETS - The invention relates to pharmaceutical compositions which contain the active agent Aliskiren and are suitable for the production of tablets by dry pressing, so that prior wet granulation can be obviated. The invention also relates to tablets which can be obtained by dry pressing of these pharmaceutical compositions and to a method for producing these tablets. The invention furthermore relates to the use of the novel pharmaceutical compositions and tablets for treating hypertension and illnesses associated therewith. | 07-07-2011 |
| 20110165236 | CONTROLLED RELEASE HYDROGEL FORMULATION - Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as controlled release dosage compositions for hydrophobic active ingredients. In one aspect, the invention provides a pharmaceutical formulation comprising a therapeutically effective amount of a hydrophobic drug, an adjustable ratio of a non-cross linked hydrogel polymer and a non-gelling insoluble polymer. One example is a controlled release pharmaceutical composition which includes 1% to 80% of a therapeutically amount of cilostazol, 4% to 80% of a water-swelling hydrogel polymer, and 4% to 80% of a non-gelling insoluble polymer. In another aspect, a constant release profile of the pharmaceutical formulation is obtained. In another aspect, a zero degree release profile of the pharmaceutical formulation is obtained. Further, a method for treating intermittent claudication using the pharmaceutical formulation is provided. | 07-07-2011 |
| 20110165237 | Protein Hydrolysate Excipients - A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water soluble protein hydrolysate to total weight of composition is provided. Whey protein hydrolysate is exemplary of a suitable soluble protein hydrolysate. A method for preparing such a composition is also provided. | 07-07-2011 |
| 20110165238 | STABILIZED ATYPICAL ANTIPSYCHOTIC FORMULATION - A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid. | 07-07-2011 |
| 20110177165 | MULTIPARTICULATE TABLET AND METHOD FOR THE PRODUCTION THEREOF - A tablet, containing | 07-21-2011 |
| 20110177166 | Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation - The present invention relates to galenic formulations wherein the active ingredient aliskiren, preferably, a hemi-fumarate salt thereof, alone or in combination with another active ingredient, is melt-granulated and is present in an amount of more than 20% by weight based on the total weight of the oral dosage form, as well as a process of preparing said solid oral dosage form. | 07-21-2011 |
| 20110189275 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110189276 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110189277 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110189278 | PTEROSTILBENE COCRYSTALS - Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals. | 08-04-2011 |
| 20110189279 | PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE PROPERTIES COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions with modified release properties comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and process of preparing such compositions. | 08-04-2011 |
| 20110189280 | DOSAGE FORM COMPRISING 1-ISOPROPYL-4-HEXAHYDRO-1H-1,4-DIAZEPINE OR A SALT THEREOF - The invention relates to a dosage form for oral administration comprising a carrier tablet, wherein the carrier tablet is at least partially (preferably partially) covered by a film comprising 1-isopropyl-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine | 08-04-2011 |
| 20110189281 | TELMISARTAN AND HYDROCHLOROTHIAZIDE COMBINATION THERAPY - A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination. | 08-04-2011 |
| 20110195119 | CONTROLLED RELEASE METFORMIN FORMULATIONS - Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration. | 08-11-2011 |
| 20110200670 | Nicotine Containing Soft Gelatin Pastilles - The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavouring agent; and about 5% to about 20% of water. | 08-18-2011 |
| 20110206766 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 08-25-2011 |
| 20110206767 | PHARMACEUTICAL COMPOSITION - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 08-25-2011 |
| 20110217373 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF GUANFACINE HYDROCHLORIDE - The present invention relates to an extended release pharmaceutical tablet composition comprising guanfacine comprising: a core containing guanfacine or a pharmaceutically acceptable salt thereof and one or more of pH-independent rate controlling polymer(s) and other pharmaceutically acceptable excipients; optionally a coating over the core as in (a) wherein, the coating comprises one or more of pH-independent rate controlling polymer(s). | 09-08-2011 |
| 20110223249 | EXTENDED RELEASE COMPOSITIONS COMPRISING MYCOPHENOLATE SODIUM AND PROCESSES THEREOF - Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases). | 09-15-2011 |
| 20110229568 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS - Described herein are peptide derivatives and peptidomimetics as inhibitors for transglutaminases, methods for their preparation, pharmaceutical compositions containing said compounds as well as uses of said transglutaminase inhibitors in particular for the treatment of coeliac disease and transglutaminase dependent diseases. | 09-22-2011 |
| 20110229569 | COMPOSITIONS EXHIBITING DELAYED TRANSIT THROUGH THE GASTROINTESTINAL TRACT - The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers. | 09-22-2011 |
| 20110229570 | ORALLY RAPIDLY DISINTEGRATING TABLET AND PROCESS FOR PRODUCING SAME - Disclosed is an orally rapidly disintegrating tablet characterized in that the tablet can be produced in a conventional tablet manufacturing facility and has a satisfactory level of hardness for practical applications, and the change in properties of the tablet (i.e., decreased in hardness of the tablet, and delay of the disintegration time of the tablet in the oral cavity) are rarely caused by factors such as humidity. The orally rapidly disintegrating tablet has hardness of 40N or more, can be disintegrated in the oral cavity within 60 seconds, and is produced by compressing of a mixture of (a) an active ingredient, (b) an excipient having good water wettability, (c) a water-insoluble polymer that is well compactible and does not substantially cause a decrease in the water wettability of the excipient and (d) a disintegrating agent. | 09-22-2011 |
| 20110236477 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 09-29-2011 |
| 20110236478 | CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME - An immediate release formulation of an active ingredient. | 09-29-2011 |
| 20110236479 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of being directly compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 09-29-2011 |
| 20110250270 | Compositions containing a capillary-active system with application-relevant diffferentiability and their use - A composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels; and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets; and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The compositions are useful, systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents. | 10-13-2011 |
| 20110250271 | SPACED DRUG DELIVERY SYSTEM - The present invention provides to a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system, wherein the time of release of the two or more therapeutically active agents is designed to provide desired control on the disease condition. The present invention also provides a method of administration of two or more therapeutically active agents comprising orally administering to a patient a spaced drug delivery system at a specified time prior to food intake by the patient. The present invention further provides a spaced drug delivery system that releases two or more antidiabetic agents at different times after oral administration, for the treatment of diabetes mellitus or conditions associated with diabetes mellitus. More particularly, the present invention provides a spaced drug delivery system that immediately releases one or more antidiabetic agents after oral administration of the system, and releases as a pulse one or more antidiabetic agents in a reliable manner at about a predetermined time after oral administration of the system. | 10-13-2011 |
| 20110250272 | SOLID, ORODISPERSIBLE AND/OR DISPERSIBLE COMPOSITION, WITHOUT AN EXCIPIENT OF KNOWN EFFECT AND ITS PROCESS OF PREPARATION - The present invention relates to a solid, orodispersible and/or dispersible composition comprising (a) from 0.1 to 59% by weight of at least one active substance with particle size no exceeding 50 μm; (b) from 40 to 99% by weight of at least one diluent without known effect, non water-soluble; (c) from 0.1 to 15% by weight of at least one disintegrating agent; and (d) from 0.05 to 10% by weight at least of one sweetening agent with particle size not exceeding 50 μm, percentages by weight being expressed compared to the total weight of the aforementioned composition. The present invention also relates to the use of said composition as a drug, a food supplement or in cosmetics and a method of preparation of an orodispersible and/or dispersible compound implementing said composition. | 10-13-2011 |
| 20110256220 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 10-20-2011 |
| 20110256221 | PHARMACEUTICAL FORMULATIONS OF OLMESARTAN - This invention is related to pharmaceutical compositions, which have good flowability properties, comprising olmesartan medoxomil or combination of olmesartan medoxomil and hydrochlorothiazide and a lubricant or mixtures of lubricants and a pharmaceutically acceptable excipient or excipients. | 10-20-2011 |
| 20110262537 | EXTENDED RELEASE DOSAGE FORM OF ROPINIROLE - There is provided an extended release tablet in tablet dosage form of ropinirole or salts thereof comprising a) an inner tablet of ropinirole or salts thereof optionally with other pharmaceutically acceptable excipients and b) an outer tablet of other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising a core of ropinirole or salt thereof and outer mantle coating comprising one or more pharmaceutically acceptable excipients. The invention also relates to processes of preparing such compositions. | 10-27-2011 |
| 20110262538 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 10-27-2011 |
| 20110268797 | MULTICOATED ALISKIREN FORMULATIONS - An oral pharmaceutical formulation of aliskiren, or a pharmaceutically acceptable salt or polymorph thereof, having at least two coating layers. | 11-03-2011 |
| 20110268798 | ORALLY DISNTEGRATING TABLETS FOR THE TREATMENT OF PAIN - An orally disintegrating tablet comprising acetylsalicylic acid, acetaminophen and caffeine and one or more pharmaceutically acceptable excipients. | 11-03-2011 |
| 20110268799 | ORAL CONTROLLED RELEASE DOSAGE FORM - A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. | 11-03-2011 |
| 20110274751 | TRIMETAZIDINE FORMULATION WITH DIFFERENT RELEASE PROFILES - A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled release, while the other layer provides immediate release. | 11-10-2011 |
| 20110274752 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF DEXLANSOPRAZOLE - Modified release oral pharmaceutical compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof in the form of a bilayer tablet and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 11-10-2011 |
| 20110274753 | DUAL RELEASE ORAL TABLET COMPOSITIONS OF DEXLANSOPRAZOLE - Dual release oral tablet compositions of dexlansoprazole or pharmaceutically acceptable salts or hydrated forms thereof and processes for the manufacture of the tablet composition and its use in the treatment of gastrointestinal disorders. | 11-10-2011 |
| 20110287098 | DISSOLUTION STABILITY OF CALCIUM CARBONATE TABLETS - The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising
| 11-24-2011 |
| 20110293715 | Pharmaceutical Formulation and Process for Its Preparation - The present invention relates to a multiparticulate tablet with improved gastro-protection comprising at least a pharmaceutically active substance in the form of enteric coated particles, and a mixture of tableting excipients, wherein the said mixture of excipients comprising xylitol and/or maltitol, each in a directly compressible form, a disintegrating agent, a lubricant and at least one other diluent and the ratio of a) the xylitol and/or the maltitol to b) the other diluent(s) is less than 5/95 (weight/weight) and the result of the “test of integrity of the film” is greater than 95%, preferably greater than 97% and more preferably still greater than 99% and the result of the “release test” is greater than 90%, preferably greater than 95%. According to one embodiment of the invention, the active substance is omeprazole or esomeprazole. According to another embodiment the tablet is a disintegratable tablet, which disintegrate in the mouth with or without chewing. The invention also comprises a process for preparing the claim tablet and its use in medicine. | 12-01-2011 |
| 20110293716 | PHARMACEUTICAL FORMULATION CONTAINING IBUPROFEN AND CODEINE - The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during the compression process. The new formulation additionally comprises talc (0.5%-5.0%) and silicified microcrystalline cellulose (30%-80%). The formulation is preferably arranged in the form of a core that comprises the active principles and, amongst others, the L-leucine, part of the talc and the silicified microcrystalline cellulose; this core is coated with a composition that contains a copolymer of methacrylic acid and ethyl acrylate. The tablets of the invention do not exhibit flaking problems, have an adequate hardness with a convenient attrition to allow for subsequent coating, offer disintegration values of less than 5 minutes, with dissolution values for both active principles in accordance with those specified for rapid-release tablets. | 12-01-2011 |
| 20110293717 | COMPACTED MOXIFLOXACIN - The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin. | 12-01-2011 |
| 20110300214 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID - The invention relates to pharmaceutical compositions comprising 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid and processes of preparing such compositions. In a second aspect, the present invention relates to a preferred pellet-layering process for preparing such compositions. | 12-08-2011 |
| 20110300215 | TABLET FORMULATION OF EZATIOSTAT - Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet. | 12-08-2011 |
| 20110311623 | COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE - The present invention relates to a composition for manufacturing an orally disintegrating dosage form that is used to prevent a coating layer of an active substance which is formed in a predetermined size in order to mask a bitter taste or an unpleasant taste. A predetermined ratio of an excipient having lower hardness than the coated active substance and another excipient having higher hardness and larger particle size than the active substance are used as means for protecting the coating layer from being destroyed. | 12-22-2011 |
| 20110311624 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEREOF - Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | 12-22-2011 |
| 20110311625 | Solid dosage forms of fenofibrate - An improved solid dosage form of fenofibrate which exhibits improved dissolution properties leading to increased bioavailability of fenofibrate. A novel core-shell approach to the composition is provided as well as a process for the preparation of the improved solid dosage forms. | 12-22-2011 |
| 20110318412 | LOW DOSE DOXEPIN FORMULATIONS, INCLUDING BUCCAL, SUBLINGUAL AND FASTMELT FORMULATIONS, AND USES OF THE SAME TO TREAT INSOMNIA - The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. | 12-29-2011 |
| 20110318413 | EXTENDED RELEASE FORMULATIONS CONTAINING DARIFENACIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF - The present invention relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof and one or more release controlling hydrophobic materials optionally coated with combination of one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials; wherein said formulation provides controlled release of the darifenacin over the period of 24 hours. The present invention further relates to an extended release formulation comprising darifenacin or pharmaceutically acceptable salts thereof, wherein darifenacin is incorporated in a matrix comprising one or more release controlling hydrophobic materials and one or more release controlling hydrophilic materials. | 12-29-2011 |
| 20120003309 | Solid Dosage Forms Of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 01-05-2012 |
| 20120003310 | DELAYED RELEASE RASAGILINE FORMULATION - Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also, disclosed are rasagiline citrate salt and the use and process of manufacture thereof. | 01-05-2012 |
| 20120009258 | COMPACTED CINACALCET - The invention relates to an intermediate, obtainable by jointly compacting (i) crystalline cinacalcet or a pharmaceutically acceptable salt thereof, with (ii) a hydrophilising agent, and also tablets containing the intermediates of the invention. The invention further relates to cinacalcet tablets with a bimodal pore size distribution and a method of preparing the tablets of the invention. Finally, the invention relates to the use of a pH adjuster for preparing cinacalcet formulations which can preferably be administered independently of mealtimes. | 01-12-2012 |
| 20120009259 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 01-12-2012 |
| 20120015028 | Controlled-Released Osmotic Pump Tablet with Lubricating Layer and the Preparation Thereof - An osmotic pump in form of controlled release tablet and the preparation thereof are disclosed Said tablet includes a double-layer tablet core consisted of a drug layer ( | 01-19-2012 |
| 20120015029 | DIRECT COMPRESSION FORMULATION AND PROCESS - This invention relates to tablets especially tablets formed by direct compression of a dipeptidylpeptidase IV (DPP-IV) inhibitor compound, a process for the preparation thereof, to new pharmaceutical formulations, and new tableting powders comprising DPP-IV inhibitor formulations capable of being directly compressed into tablets. The invention relates further to a process for preparing the tablets by blending the active ingredient and specific excipients into the new formulations and then directly compressing the formulations into the direct compression tablets. The invention also relates to vildagliptin particle size distribution and a new crystal form of vildagliptin particularly adapted for the preparation of improved tablets and other pharmaceutical compositions. | 01-19-2012 |
| 20120015030 | MODIFIED RELEASE FORMULATIONS CONTAINING DRUG-ION EXCHANGE RESIN COMPLEXES - A solid dose composition containing a mixture of a cured, modified release-barrier coated methylphenidate-ion exchange resin complex-matrix and an uncoated methylphenidate-ion exchange resin complex is described. The barrier coated methylphenidate-ion exchange resin complex-matrix comprises methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin to form the complex which is admixed with a polymer to form a methylphenidate-ion exchange resin complex-matrix, which is subsequently coated with a modified release coating. The modified coating contains polyvinyl acetate polymer and a plasticizer and is cured. | 01-19-2012 |
| 20120021054 | TABLET FORMULATION OF EZATIOSTAT - Disclosed herein are tablets comprising ezatiostat hydrochloride wherein the ezatiostat hydrochloride comprises from about 75 to about 82 percent by weight of the tablet. | 01-26-2012 |
| 20120027853 | PROCESS FOR PREPARATION OF ANTI-TUBERCULAR COMBINATION AND PHARMACEUTICAL COMPOSITION PREPARED THEREFROM - This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability. | 02-02-2012 |
| 20120027854 | PHARMACEUTICAL COMPOSITION COMPRISING EZETIMIBE AND SIMVASTATIN - The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing simvastatin and ezetimibe, comprising the steps of providing a first composition containing simvastatin, providing a second composition containing ezetimibe, and forming a dosage form comprising at least two separate compartments, wherein one compartment is formed using either the first or the second composition and another compartment is formed using the other composition. The present invention also relates to a process for preparing dosage forms containing simvastatin and ezetimibe, wherein the process involves a direct compression step. Furthermore, the present invention belongs to a dosage form obtained by this process, comprising at least two separate compartments, wherein one compartment contains simvastatin and one compartment contains ezetimibe. Finally, the present invention relates to a combination dosage form comprising a combination of simvastatin and ezetimibe present in two separate compartments of the dosage form. | 02-02-2012 |
| 20120027855 | PHARMACEUTICAL COMPOSITIONS FOR GASTROINTESTINAL DRUG DELIVERY - The present invention relates to controlled release pharmaceutical formulations of active principle(s) like tetracycline-class antibiotics for providing increased residence time in the gastrointestinal tract and the process of preparing them. | 02-02-2012 |
| 20120034302 | PARTICULATE COMPOSITION AND THE METHOD OF MAKING THE SAME - A particulate material for delivering an active ingredient and a method for making the same is provided. The particulate material can be included in a solid dosage form to provide both high tablet strength and smooth-dissolving mouth-feel. The particulate material includes at least two low moldability sugars, such as, dextrose and sucrose, in an amount of from about 70% to about 100% of the particulate material and is granulated in the presence of a binding agent. | 02-09-2012 |
| 20120058183 | RETIGABINE TABLETS, PREFERABLY HAVING MODIFIED RELEASE - The invention relates to tablets, especially tablets with modified release, containing (a) retigabine and a combination of (b) water-soluble excipient and (c) non-water-soluble excipient; and a process for producing them. | 03-08-2012 |
| 20120064157 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition. | 03-15-2012 |
| 20120064158 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. Said composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method of improving the dissolution properties of a pharmaceutical composition containing olmesartan medoxomil and amlodipine besylate by using said composition is also provided. | 03-15-2012 |
| 20120064159 | Multilayer Oral Tablets Containing a Non-Steroidal Anti-Inflammatory Drug and/or Acetaminophen - Multilayer tablets of a non-steroidal anti-inflammatory drug (NSAID) and/or acetaminophen for oral administration containing an immediate release layer or layers containing a NSAID and/or acetaminophen and/or a second therapeutic agent and an extended release layer containing a NSAID and/or acetaminophen are provided. Multilayer tablets containing an additional immediate and/or extended release layer of a second therapeutic agent are also provided. Methods for production of these multi-layer tablets and methods for their use in treating a subject in need of a NSAID and/or acetaminophen are also provided. | 03-15-2012 |
| 20120070495 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 03-22-2012 |
| 20120087978 | DOSAGE FORMS OF APIXABAN - The present invention relates to a Factor Xa inhibitor dosage form comprising apixaban in a solubility-improved form wherein the dosage form provides controlled release of apixaban and methods for preventing or treating venous thromboembolisms, deep vein thrombosis and acute coronary syndrome with said dosage form. | 04-12-2012 |
| 20120093927 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 04-19-2012 |
| 20120100211 | MATERIAL AND PROCESS FOR INCORPORATION OF LOW DOSAGE ACTIVE PHARMACEUTICAL INGREDIENTS AND USE THEREOF - A low dose API pharmaceutical tablet having excellent content uniformity is provided. The tablet is formed by spray coating a support excipient with the API. The resulting composition is suitable for direct compression tablet formulation without the need for an additional granulation step to uniformly coat the API onto the support excipient. The support excipient comprises microcrystalline cellulose, a binder and a disintegrant, and is formed by spraying a homogeneous slurry of the support excipient components. | 04-26-2012 |
| 20120107398 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and pioglitazone, processes for the preparation thereof, and their use to treat certain diseases. | 05-03-2012 |
| 20120107399 | PROCESS FOR DRYING OF BIBW2992, OF ITS SALTS AND OF SOLID PHARMACEUTICAL FORMULATIONS COMPRISING THIS ACTIVE INGREDIENT - The present invention relates to a drying process of BIBW 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising BIBW2992 or a salt thereof, and to pharmaceutical compositions comprising BIBW 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (Karl-Fischer) of not more than 4.2%. | 05-03-2012 |
| 20120114752 | STABLE TABLET CONTAINING 4,5-EPOXYMORPHINAN DERIVATIVE - The present invention relates to a stable tablet comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an effective ingredient. That is, the tablet according to the present invention comprises: (1) as the effective ingredient, a specific 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt; (2) sodium thiosulfate; (3) at least one selected from the group consisting of saccharides and sugar alcohols; and (4) crospovidone, sodium carboxymethyl starch or a mixture thereof, in which tablet the content of the aforementioned (4) is 1 to 20% by weight per unit weight containing the aforementioned effective ingredient. | 05-10-2012 |
| 20120121703 | TABLET CONTAINING FERRIC CITRATE - The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer. | 05-17-2012 |
| 20120128773 | DESFESOTERODINE IN THE FORM OF A TARTARIC ACID SALT - The invention concerns desfesoterodine in the form of a tartaric acid salt, in particular in the polymorphic “R form”, as well as a process for its production. In a second aspect, the invention concerns the desfesoterodine of the invention in a microencapsulated form. | 05-24-2012 |
| 20120135076 | INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS - An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 μm, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape. | 05-31-2012 |
| 20120141586 | THROMBIN RECEPTOR ANTAGONIST AND CLOPIDOGREL FIXED DOSE TABLET - The present invention provides for a pharmaceutical formulation which comprises a) a compound of the formula (I): SCH 530348 or the bisulfate salt thereof; b) clopidogrel; and c) silicified microcrystalline cellulose. | 06-07-2012 |
| 20120156293 | ANTACID AND LAXATIVE TABLET - A tablet having excellent disintegration properties, as a tableted product, for a long time and has excellent shape-retention stability by the improvement of the strength of the tablet. The antacid and laxative tablet comprises magnesium oxide particles as the main component, wherein (a) the average secondary particle diameter measured by a laser diffraction scattering method of the magnesium oxide particles is 0.5 to 10 μm, (b) the content of the magnesium oxide particles is 85 to 96 wt %, (c) the content of crystalline cellulose as a binder is 2 to 8 wt %, (d) the content of croscarmellose sodium as a disintegrating agent-I is 0.8 to 2.5 wt %, (e) the content of insoluble polyvinyl pyrrolidone as a disintegrating agent-II is 1 to 3.5 wt %, and (f) the content of a lubricant is 0.5 to 2 wt %. | 06-21-2012 |
| 20120164219 | PERORAL TABLET FOR BOWEL CLEANSING - To provide a peroral tablet for bowel cleansing which leaves no remains in the intestinal tract after bowel cleansing, which exhibits a dissolution property equivalent to that of conventional sodium phosphate-containing tablets including crystalline cellulose, and which is a small-size agent readily taken by a subject. | 06-28-2012 |
| 20120177734 | Delayed Release Tablet with Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 07-12-2012 |
| 20120183610 | GLUCOCORTICOID THERAPY - The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects. | 07-19-2012 |
| 20120189693 | ORAL DOSAGE FORMS - Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm. | 07-26-2012 |
| 20120189694 | CO-PRECIPITATE COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5-INHIBITOR) AND A PHARMACEUTICALLY COMPATIBLE CARRIER, PRODUCTION AND USE THEREOF - The invention relates to a co-precipitate comprising a phosphodiesterase-5 inhibitor (PDE-5-inhibitor) and a pharmaceutically compatible copolymer carrier comprising 2 or more different acrylic acid derivatives, a method for production thereof and a medication comprising the co-precipitate according to the invention, a method for producing said medication and the use of said medication for treating an illness wherein the inhibiting of phosphodiesterase-5 is of therapeutic benefit. | 07-26-2012 |
| 20120189695 | PHARMACEUTICAL DOSAGE FORM - This invention relates to a oral pharmaceutical formulation for methylphenidate or its analogs, derivatives, isomers or enantiomers, including d-threo-methylphenidate. | 07-26-2012 |
| 20120189696 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME - A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more. | 07-26-2012 |
| 20120195966 | ORAL DOSAGE FORM FOR MODIFIED RELEASE COMPRISING A JAK3 INHIBITOR - The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms. | 08-02-2012 |
| 20120201883 | ANTIVIRAL COMPOSITONS - A composition which includes a carboxamide, preferably ribavirin, for treating viral diseases in humans. A preferred embodiment of the subject invention comprises a very high dose (>600 mg) of ribavirin, and more preferably between about 800-1200 mg of ribavirin or more per dosage form. | 08-09-2012 |
| 20120201884 | EXTRACTS, FRACTIONS AND COMPOSITIONS COMPRISING ACETOGENINS AND THEIR APPLICATIONS - The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal α,β-unsaturated-γ-methyl-γ-lactone moiety derived from | 08-09-2012 |
| 20120201885 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE - This invention relates to a bilayer pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and pioglitazone, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions. | 08-09-2012 |
| 20120207831 | COATED SOLID DOSAGE FORMS - The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage. | 08-16-2012 |
| 20120213850 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 08-23-2012 |
| 20120213851 | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING AN INTEGRASE INHIBITOR - Compressed tablets for oral administration containing raltegravir in the form of a pharmaceutically acceptable salt are described. The tablets comprise: (A) an intragranular component comprising (i) an effective amount of an alkali metal salt of raltegravir, (ii) optionally a first superdisintegrant, and (iii) a binder; and (B) an extragranular component comprising (i) a second superdisintegrant, (ii) a filler, and (iii) a lubricant. Methods for preparing the tablets and the use of the tablets, optionally in combination with other anti-HIV agents, for the inhibition of HIV integrase, for the treatment or prophylaxis of HIV infection, or for the treatment, delay in the onset, or prophylaxis of AIDS are also described. | 08-23-2012 |
| 20120219622 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 08-30-2012 |
| 20120219623 | PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN - The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin. | 08-30-2012 |
| 20120231077 | Coated Tablets, Their Method of Preparation, and Related Uses - A tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. In particular, a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid. | 09-13-2012 |
| 20120237600 | MULTILAYER PHARMACEUTICAL COMPOSITION THAT CAN BE DISPERSED IN WATER AND WHICH CONTAINS A COMBINATION OF ANTIMALARIAL AGENTS - The present invention relates to a multilayer pharmaceutical composition that can be dispersed in water, containing one antimalarial agent in combination with at least one other antimalarial agent. The present invention also relates to a method for producing such a pharmaceutical composition. | 09-20-2012 |
| 20120251622 | CELLULOSE GUM AND POLYOL TROCHE - A troche with 2.5-6% cellulose gum and at least 75% polyol molecules is disclosed. It may be an adherent troche, preferably adhered to teeth or gums or cheek with acacia gum. Consumers are instructed to use the troches to relieve the sensations of dry mouth, particularly while sleeping. The polyol molecules are preferably xylitol. The troches may be made with a bi-layer tablet press rounded on one side and flat on the other, preferably using acacia gum in the flat side layer for adhesion. | 10-04-2012 |
| 20120251623 | METHOD OF ADMINISTERING AN ACTIVE INGREDIENT USING A CHEWABLE ORAL DOSAGE FROM COMPRISING TEXTURE MASKED PARTICLES - In one aspect, the present invention features a method of administering an active ingredient, said method comprising chewing an oral dosage form comprising a texture masked particle, said texture masked particle comprising a) a core containing an active ingredient; b) a first coating layer comprised of a taste masking agent that substantially covers the core, wherein said taste masking agent is comprised of an insoluble film forming polymer and a non-enteric, water soluble polymer; and c) a second coating layer on the surface of the first coating layer. | 10-04-2012 |
| 20120258171 | COMPOSITION COMPRISING FESOTERODINE AND FIBER - The invention relates to a pharmaceutical composition containing (a) fesoterodine and/or fesoterodine metabolites and (b) fibers, wherein the weight ratio of components (a):(b) is in the range from 1:50 to 1:2; and oral dosage forms containing the pharmaceutical composition. The invention further relates to dry methods of preparing those dosage forms. | 10-11-2012 |
| 20120263789 | DELAYED RELEASE RASAGILINE FORMULATION - Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. | 10-18-2012 |
| 20120276199 | TASTE MASKED PHARMACEUTICAL FORMULATIONS - The present invention relates to taste masked pharmaceutical formulations, processes for preparing the same and methods of using them. The present invention relates to taste masked effervescent formulations comprising fexofenadine or a pharmaceutically acceptable salt thereof, processes for preparing the same, and therapeutic uses and methods of treatment employing such formulations. | 11-01-2012 |
| 20120276200 | FORMULATIONS OF QUINOLINONES - A pharmaceutical formulation, comprising: a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, or a mixture thereof, | 11-01-2012 |
| 20120282335 | RAPIDLY DISPERSING GRANULES, ORALLY DISINTEGRATING TABLETS AND METHODS - This invention relates to rapidly dispersing microgranules comprising at least one sugar alcohol or saccharide, at least one super disintegrant, and a pharmaceutically acceptable additive with multi-functionality (e.g., starch acting as a binder, disintegrant, diluent/filler, glidant, etc) at a low level, which can be formed by not only eliminating a wet milling step but also avoiding an extensive dry milling step. Furthermore, such rapidly dispersing microgranules could also comprise a pharmaceutically active agent thereby providing for a pharmaceutical composition, or the rapidly dispersing microgranules thus produced are suitable for blending with a pharmaceutically active agent that is optionally taste-masked and/or controlled release coated microparticles to also provide for a pharmaceutical composition and the invention is also directed to a method for manufacturing such rapidly dispersing microgranules in a high useable yield, as well as orally disintegrating tablets comprising such rapidly dispersing microgranules. The rapidly dispersing microgranules are also free flowing. | 11-08-2012 |
| 20120282336 | BILAYER TABLET FORMULATIONS - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 11-08-2012 |
| 20120288563 | AMORPHOUS DARUNAVIR - Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient. | 11-15-2012 |
| 20120294939 | DIRECT COMPRESSION FORMULATION AND PROCESS - Dipeptidylpeptidase IV inhibitor (herein referred to as DPP-IV) that may be 98.5-100% pure is a high-dose drug capable of direct compressed with specific excipients into sold form dosage forms, such as tablets and capsules having desired, hardness, disintegrating ability and acceptable dissolution characteristics. DPP-IV is not inherently compressible and thus present formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and weight control. The binder used ensures sufficient cohesive properties that allow DPP-IV to be compressed using the direct compression method. The tablets produced provide an acceptable in vitro dissolution profile. | 11-22-2012 |
| 20120294940 | RAPIDLY DISINTEGRATING TABLET IN ORAL CAVITY - The present invention provides a method of suppressing the bitter taste of a drug when a rapidly disintegrating tablet in an oral cavity is produced. | 11-22-2012 |
| 20120301546 | ACID-RESISTANT SOFT GEL COMPOSITIONS - The present disclosure describes a delivery device for administration of nutraceuticals or pharmaceuticals, which device contains a soft gel shell comprising a gelatin-based water soluble film forming polymer, an acid insoluble polymer, and at least one reducing sugar and water, including processes, gel mixtures used for device production, and coatings containing such gel mixtures. | 11-29-2012 |
| 20120301547 | PALIPERIDONE DOUBLE-LAYERED OSMOTIC PUMP CONTROLLED RELEASE TABLET AND PREPARATION METHOD THEREOF - A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage. | 11-29-2012 |
| 20120321710 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 12-20-2012 |
| 20130004575 | CONTROLLED RELEASE FORMULATIONS USING INTELLIGENT POLYMERS - A controlled release pharmaceutical composition comprises (a) topiramate or a pharmaceutically acceptable salt thereof, (b) a first intelligent polymer component; and (c) a second intelligent polymer component having opposite wettability characteristics to the first intelligent polymer component. The polymer components are effective for controlled release of the pharmaceutically active substance from the composition. | 01-03-2013 |
| 20130004576 | RIFAXIMIN POWDER, PROCESS FOR PREPARING THE SAME AND CONTROLLED RELEASE COMPOSITIONS CONTAINING SAID RIFAXIMIN USEFUL FOR OBTAINING A LONG-LASTING EFFECT - The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient. | 01-03-2013 |
| 20130011477 | Stable Pharmaceutical Composition of Imatinib - The present invention relates to a compressed film-coated tablet comprising imatinib its pharmaceutically acceptable salts there of in an amount of more than 80% based on the total weight of the finished dosage form. | 01-10-2013 |
| 20130017262 | IMMEDIATE/DELAYED DRUG DELIVERYAANM Mullen; AlexanderAACI GlasgowAACO GBAAGP Mullen; Alexander Glasgow GBAANM Stevens; HowardAACI GlasgowAACO GBAAGP Stevens; Howard Glasgow GBAANM Eccleston; SarahAACI GlasgowAACO GBAAGP Eccleston; Sarah Glasgow GB - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released immediately following administration and again at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released before sleep and whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for an immediate, followed by a delayed release of drug. | 01-17-2013 |
| 20130022675 | DRUG DELIVERY SYSTEM - A novel encapsulated product is provided and includes: at least one pharmaceutical; at least one compressible material; and at least one tableting material; wherein the encapsulated product is in the form of a caplet having a diameter of from about 1 millimeter to about 7 millimeters and a length from about 1 millimeter to about 7 millimeters. A method for preparing the encapsulated product is also provided. | 01-24-2013 |
| 20130022676 | PULSATILE DRUG RELEASE - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a pulse at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a pulsed release of drug. | 01-24-2013 |
| 20130022677 | DELAYED PROLONGED DRUG DELIVERY - In one aspect, the present invention is concerned with a treatment where it is desired that an active agent is designed to be released in a prolonged manner at a time point some time after administration of the active agent. The present invention is particularly suited to administering an agent which may be released whilst a subject is sleeping, shortly before waking and continues to administer the drug during the early waking hours. As well as treating certain conditions by a particular regime, the invention also provides novel formulations for a delayed, followed by a prolonged release of drug. | 01-24-2013 |
| 20130022678 | ORAL CONTROLLED RELEASE DOSAGE FORM - A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride. | 01-24-2013 |
| 20130022679 | Controlled Release and Taste Masking Oral Pharmaceutical Composition - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 01-24-2013 |
| 20130028971 | Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections - The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided. | 01-31-2013 |
| 20130028972 | Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising
| 01-31-2013 |
| 20130028973 | PARTICULATE COMPRISING A CALCIUM-CONTAINING COMPOUND AND A SUGAR ALCOHOL - The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets. | 01-31-2013 |
| 20130028974 | PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN - Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia. | 01-31-2013 |
| 20130039982 | LOW-DOSE TABLETS AND PREPARATION PROCESS - The invention concerns a microgranule tablet comprising a low dose of active principle containing a directly compressible diluent. The invention is characterised in that the directly compressible diluent consists exclusively of neutral microgranules, and the active principle is set on the neutral microgranules and is not coated with an agent designed to modify its release or mask its taste. | 02-14-2013 |
| 20130045276 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 02-21-2013 |
| 20130059003 | SUSTAINED RELEASE DONEPEZIL FORMULATIONS - Sustained release formulations comprising donepezil, or its pharmaceutically acceptable salts, and methods of preparing the sustained release formulations. | 03-07-2013 |
| 20130059004 | ORAL DRUG DELIVERY SYSTEM - An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a reactive composition located in an immediate vicinity of one or more preselected surfaces. The coating is operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces. | 03-07-2013 |
| 20130059005 | BUPROPION HYDROBROMIDE POLYMORPHS - Polymorphous and amorphous forms of bupropion hydrobromide are described. | 03-07-2013 |
| 20130064887 | PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. | 03-14-2013 |
| 20130064888 | PHARMACEUTICAL FORMULATIONS - The present invention provides a pharmaceutical dosage form in the form of a tablet comprising: (a) a compressed inert core, (b) an optional subcoat over the compressed inert core, (c) a drug layer over the compressed core (a) or optional subcoat (b) comprising a drug having a water solubility at 25° C. of about 100 mg/l or less, a coating polymer and optionally a surfactant, and (d) optionally one or more layers coating the drug layer. The present invention also provides a process of making the same. | 03-14-2013 |
| 20130064889 | Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof - Tablet-in tablet paliperidone formulations and processes for preparation and use thereof are provided. | 03-14-2013 |
| 20130064890 | PHARMACEUTICAL FORMULATION BASED ON IBUPROFEN AND CODEINE HAVING IMPROVED STABILITY - Pharmaceutical formulation based on ibuprofen and codeine having improved stability. The invention consists of a novel pharmaceutical formulation having the form of tablets or similar comprising a core composed of an association of ibuprofen and codeine as active ingredients, together with an excipient including at least a diluent, a disintegrating agent, a fluidizing agent and a lubricant which is sodium stearyl fumarate. Said core is coated with a composition based on one or several polymers of diverse modified cellulose ethers and polymers derived from acrylic and methacrylic acids, a plasticiser and, an opacifier or colouring agent and any of the mixtures thereof. These characteristics render the tablets of the invention more efficacious and safe having the form of more stable preparations, without this fact implying greater technological complexity. | 03-14-2013 |
| 20130064891 | PHARMACEUTICAL COMPOSITIONS OF NSAID AND ACID INHIBITOR - The present invention relates a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients, wherein non-steroidal anti-inflammatory drug is present in two or more portions. More particularly, the invention relates to compositions comprising Esomeprazole and Naproxen and a process for preparation thereof. Further invention relates to a pharmaceutical composition comprising esomeprazole magnesium dihydrate, non-steroidal anti-inflammatory drug and one or more pharmaceutically acceptable excipients wherein, esomeprazole magnesium dihydrate and non-steroidal anti-inflammatory drug provides co-ordinated release. | 03-14-2013 |
| 20130071476 | Rapid Melt Controlled Release Taste-Masked Compositions - Rapid melt tablets that dissolve and release an active component in the oral cavity are comprised of a pharmaceutical active ingredient such as dextromethorphan complexed with a resin that is effective in taste-masking the otherwise bitter taste of the active making it convenient for oral administration. The drug/resin-complexed particles can be coated with water swellable or water insoluble polymers to impart controlled release properties to the active ingredient. A rapid melt tablet also comprises diluents, sweeteners, flavors, disintegrants and other excipients to form granules that can be compressed into tablets at low pressure without the need for a binding agent. | 03-21-2013 |
| 20130084333 | ABUSE RESISTANT ORAL DOSAGE FORMS - Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist. | 04-04-2013 |
| 20130089608 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs - The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions. | 04-11-2013 |
| 20130095181 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIODIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 04-18-2013 |
| 20130115288 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 05-09-2013 |
| 20130122088 | TABLET FORMULATIONS CONTAINING 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE SALTS AND TABLETS MADE THEREFROM - Pharmaceutical formulations containing a salt of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, which are suitable for forming into a tablet dosage form, as well as tablet dosage forms are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 05-16-2013 |
| 20130122089 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 05-16-2013 |
| 20130122090 | Multiple Unit Tablet Composition - A multiple unit tablet composition comprising an enteric coated multiple unit cores comprising a pharmaceutically active ingredient, wherein plasticizer content of enteric coating is less than about 10% by weight of the enteric coating polymer; at least two diluents and optionally one or more other pharmaceutically acceptable excipient, wherein one diluent is highly compactable microcrystalline cellulose and process for preparing the same. | 05-16-2013 |
| 20130129823 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 05-23-2013 |
| 20130129824 | Solid Drug Tablets for Implantable Drug Delivery Devices - A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesethetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another. | 05-23-2013 |
| 20130142873 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-- 3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE - Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition. | 06-06-2013 |
| 20130156854 | Controlled Release Pharmaceutical Compositions of Milnacipran - A controlled release pharmaceutical compositions comprising Milnacipran or pharmaceutically acceptable salts there—of is provided. The pharmaceutical composition comprises an immediate release core comprising Milnacipran or pharmaceutically acceptable salts thereof, pharmaceutically acceptable excipients and a coating on the immediate release core comprising rate controlling agents. | 06-20-2013 |
| 20130164376 | FORMULATIONS OF (+)-2-[1-(3-ETHOXY-4-METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL]-4-ACETYLAMI- NOISOINDOLINE-1,3-DIONE - Pharmaceutical compositions and single unit dosage forms of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate thereof, are provided herein. Also provided are methods of treating, managing, or preventing various diseases or disorders. | 06-27-2013 |
| 20130171254 | FAST DISSOLVING PHARMACEUTICAL COMPOSITION COMPRISING LORNOXICAM - The present invention discloses a fast dissolving pharmaceutical composition comprising lornoxicam or pharmaceutically acceptable salts thereof as an active ingredient along with at least one alkalinizer, at least one organic acid and at least one pharmaceutically acceptable excipient. The present invention also discloses processes of preparing fast dissolving pharmaceutical composition. | 07-04-2013 |
| 20130177645 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 07-11-2013 |
| 20130183382 | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same - The present invention relates to fexofenadine granules, to a composition containing them and to a process for the hot-melt coating of fexofenadine. The process for the hot-melt coating of fexofenadine allows efficient masking of its bitter taste without, however, unacceptably slowing down its dissolution. | 07-18-2013 |
| 20130189358 | SAXAGLIPTIN PHARMACEUTICAL FORMULATIONS - The present invention includes a compressed solid dosage form comprising saxagliptin or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the at least one pharmaceutically acceptable excipient optionally comprises at least one organic acid. | 07-25-2013 |
| 20130189359 | Wet Granulation Using a Water Sequestering Agent - Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process. | 07-25-2013 |
| 20130189360 | COMPRESSED COMPOSITION - An object of the present invention is to provide a compressed composition that is superior in terms of maintaining the function of a film or in terms of content uniformity even during tableting process. | 07-25-2013 |
| 20130195976 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 08-01-2013 |
| 20130195977 | Low Concentration Meloxicam Tablets - A solid tablet formed through direct compression of powder, the powder comprising meloxicam as an active ingredient and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the meloxicam. | 08-01-2013 |
| 20130202697 | CHIMERIC SURFACE ACTIVE PROTEINS - The present invention relates to a nucleic acid molecule encoding a chimeric protein having the biochemical activity of a surface active protein, wherein said chimeric protein comprises: (a) an N-terminal portion of a first surface active protein, wherein the N-terminal portion is devoid of between 0 and 10 of the most N-terminal amino acids of the mature first surface active protein; and, C-terminally thereof, (b) a C-terminal portion of a second surface active protein, wherein the C-terminal portion is devoid of between 0 and 10 of the most C-terminal amino acids of the mature second surface active protein. The present invention further relates to a vector, a non-human host and a method for the production of a chimeric protein having the biochemical activity of a surface active protein. In addition, the present invention relates to a chimeric protein encoded by the nucleic acid molecule of the invention and a composition comprising the chimeric protein. The chimeric protein may only consist of the above mentioned core of (a) and (b), but may also be flanked by additional components of the core, i.e. (a) or (b) or by (an) additional complete core(s) (a) and (b). The present invention furthermore relates to a method of coating and/or impregnating a material, comprising contacting the material with the chimeric protein or the composition of the invention. | 08-08-2013 |
| 20130202698 | L-ORNIDAZOLE FORMULATIONS AND THEIR APPLICATIONS IN TREATMENT OF PARASITIC INFECTIONS - This invention relates to new methods of treating parasitic infections, such as trichomonas vaginalis infection and cecum amoeba infection, using L-enantiomer enriched ornidazole, in particular enantiomerically pure L-ornidazole, which provides benefits such as higher efficacy and lower toxicity to central nervous system over the existing racemic Ornidazole drug. New methods of synthesizing L- and D-enantiomers of Ornidazole in high purity and enantiomeric excess (ee), new formulations of the enantiomerically enriched L- or D-ornidazole, as well as their preparation processes and methods of use, are also disclosed. | 08-08-2013 |
| 20130209558 | Oral Dosage Forms of Bendamustine and Therapeutic Use Thereof - In the present invention there is provided a pharmaceutical composition for oral administration which comprises bendamustine or a pharmaceutically acceptable, ester, salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable excipient and which shows a dissolution of the bendamustine of at least 60% in 20 minutes, 70% in 40 minutes and 80% in 60 minutes, as measured with a paddle apparatus at 50 rpm according to the European Pharmacopoeia in 500 ml of a dissolution medium at a pH of 1.5, and wherein the pharmaceutically acceptable excipient is either a pharmaceutically acceptable non-ionic surfactant, selected from the group consisting of a polyethoxylated castor oil or derivative thereof and a block copolymer of ethylene oxide and propylene oxide or a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. The invention further relates to the above pharmaceutical composition for use for the oral treatment of a medical condition which is selected from chronic lymphocytic leukemia, acute lymphocytic leukaemia, chronic myelocytic leukaemia, acute myelocytic leukaemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, breast cancer, ovarian cancer, small cell lung cancer and non-small cell lung cancer. The invention moreover relates to the above pharmaceutical composition for the above use wherein the dosage regimen comprises at least the administration of a dose of 100 to 600 mg/m2/per person of bendamustine on day 1 and day 2, optionally a dose of 50 to 150 mg/m | 08-15-2013 |
| 20130209559 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 08-15-2013 |
| 20130224295 | GRANULE AND ORALLY-DISINTEGRATING TABLET CONTAINING DRUG CAUSING BITTERNESS - It is an object of the present invention to provide a powder, a granule, an orally-disintegrating tablet, and the like that contain a drug causing bitterness, and that can suppress the bitterness in the mouth and improve solubility thereof in the stomach. The present invention provides a drug-containing granule comprising (a) a core particle that contains a drug causing bitterness, and (b) a masking coating that coats the core particle, | 08-29-2013 |
| 20130224296 | Drug Formulations Using Water Soluble Antioxidants - The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin cross-linking) during the manufacturing process and/or during shelf-life storage. | 08-29-2013 |
| 20130236543 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases. | 09-12-2013 |
| 20130236544 | STABLE PHARMACEUTICAL COMPOSITIONS OF FESOTERODINE - The present invention relates to stable pharmaceutical compositions comprising fesoterodine or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine or a pharmaceutically acceptable salt thereof and a stabilizer. The invention also relates to processes for making such compositions and the methods of using such compositions. | 09-12-2013 |
| 20130243856 | ORAL DRUG DELIVERY SYSTEM - An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a swellable composition located in an immediate vicinity of one or more preselected surfaces. The coating comprises a defect wherein said defect is not a passageway through the preselected portion of the coating and operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces. | 09-19-2013 |
| 20130243857 | THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE - The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV. | 09-19-2013 |
| 20130243858 | COMPOUND FORMULATIONS - Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods. | 09-19-2013 |
| 20130243859 | ORALLY DISINTEGRATING TABLET - The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. | 09-19-2013 |
| 20130251794 | Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same - The present invention relates to a method for “hot melt coating” of pharmaceutical active ingredients characterized by organoleptic or physicochemical properties that it is desirable to mask. | 09-26-2013 |
| 20130251795 | PHARMACEUTICAL COMPOSITIONS CONTAINING A BIGUANIDE AND A LOW DOSE ANTIDIABETIC AGENT - The present invention relates to pharmaceutical compositions that include a combination of a biguanide present in an extended-release form and a low dose antidiabetic agent present in an immediate-release form. The present invention further relates to processes for preparing such compositions. | 09-26-2013 |
| 20130259935 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLIMEPIRIDE AND POLYETHYLENE GLYCOL CASTOR OIL - The present invention relates to the field of a pharmaceutical technology. More specifically, the present invention relates to a pharmaceutical composition comprising glimepiride and a surface active agent. Surface active agent obtainable by reacting castor oil or hydrogenated castor oil with ethylene oxide, preferably hydrogenated castor oil, substantially improves dissolution glimepiride active pharmaceutical ingredient and at the same time, when both formulated into a pharmaceutical composition, ensures satisfying or exceeding other parameters like for example stability, hardness, friability and handling of said pharmaceutical composition. | 10-03-2013 |
| 20130259936 | LOW-DOSE DOXEPIN FORMULATIONS AND METHODS OF MAKING AND USING THE SAME - The invention disclosed herein generally relates to low-dose oral doxepin pharmaceutical formulations and the use of these formulations to promote sleep. | 10-03-2013 |
| 20130259937 | AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS - Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids and matrix-forming polymers, which are used to encapsulate various drugs and active ingredients. The chewable sustained release compositions can maintain their sustained release properties even after being fragmented into a plurality of pieces. | 10-03-2013 |
| 20130266646 | PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS - The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 | 10-10-2013 |
| 20130266647 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 10-10-2013 |
| 20130266648 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 10-10-2013 |
| 20130266649 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 10-10-2013 |
| 20130273156 | ORAL PHARMACEUTICAL TABLET FOR CONTROLLED RELEASE OF MESALAZINE AND PROCESS FOR OBTAINING IT - The invention provides an oral pharmaceutical tablet for controlled release of mesalazine or a pharmaceutically acceptable salt thereof as active ingredient with a core and a gastro-resistant outer coating, wherein the core comprises mesalazine and a hydrophilic matrix consisting of a mixture of hydroxypropylmethyl cellulose (HPMC) having a different viscosity and the gastro-resistant outer coating comprises a pH-dependent release polymer, with the pharmaceutically acceptable excipients. The invention also refers to the process for obtaining said oral pharmaceutical tablet and to said oral pharmaceutical tablet of controlled release of mesalazine for treating ulcerative colitis. | 10-17-2013 |
| 20130273157 | ORALLY DISINTEGRATING TABLET - A orally disintegrating tablet is obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity. | 10-17-2013 |
| 20130280326 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INTENDED TO PREVENT MISUSE - The present invention is directed to oral pharmaceutical forms, the composition of which makes it possible to prevent possible misuse of the active principle present therein. The present invention thus relates to a pharmaceutical composition for oral administration intended to prevent abuse of use at the expense of a third party. | 10-24-2013 |
| 20130295175 | ORALLY DISINTEGRATING TABLET - The present invention features a tablet containing at least one first material, at least one second material, and at least one pharmaceutically active agent, wherein: | 11-07-2013 |
| 20130302417 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 11-14-2013 |
| 20130315993 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release. | 11-28-2013 |
| 20130330406 | Bilayer Tablet Formulations - The present invention relates to bilayer tablet formulations comprising metformin extended release (XR) or reduced mass metformin XR formulation as the first layer, an SGLT2 inhibitor formulation as the second layer, and optionally a film coating. The present invention provides methods of preparing the bilayer tablet formulations and methods of treating diseases or disorders associated with SGLT2 activity employing the bilayer tablet formulations. | 12-12-2013 |
| 20130330407 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 12-12-2013 |
| 20130330408 | SOLID PARTICULATE COMPOSITIONS COMPRISING COENZYME Q10 - The present invention generally relates to improvements in the bioavailability and/or solubility of coenzyme Q10. For example, the present invention relates to methods for preparing particulate compositions including coenzyme Q10 that generally comprise dispersing and/or dissolving the coenzyme Q10 throughout a suitable solvent, and combining the coenzyme Q10 and an encapsulating (e.g., microencapsulating) agent. The present invention also generally relates to particulate compositions comprising coenzyme Q10 that exhibit improved bioavailability and/or solubility as compared to previous coenzyme Q10 products. | 12-12-2013 |
| 20130344144 | LOW FLUSH NIACIN FORMULATION - The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment. | 12-26-2013 |
| 20130344145 | ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF - A pharmaceutical composition or formulation adapted for oral administration in tablet, coated tablet, capsule or reconstitutable powder form for the prevention or treatment of intestinal disorders such irritable bowel syndrome, also known as irritable colon syndrome, based on an intestinal motility modifier, an agent that prevents gas retention, of digestive enzymes, a binding agent, a diluting agent, an absorbent agent, a lubricant, aglidant, and an disintegrating agent or suspending agent, effective in the normalization of intestinal disorders, to achieve an analgesic activity, to achieve an anti-spasmic activity and to reduce the symptoms associated with intestinal gas such as distention, abdominal pain and flatulence. | 12-26-2013 |
| 20130344146 | DRY FORMULATIONS OF ARIPIPRAZOLE - The invention encompasses dry compression pharmaceutical compositions of aripiprazole, methods of making tablets from the compositions, and tablets of the dry compression pharmaceutical composition. | 12-26-2013 |
| 20130344147 | TABLET-FORMED PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR PRODUCING SAME - The object of the present invention is to provide an adsorbent for oral administration, which can: obviate sandy texture of granules-formed adsorbent for oral administration, reduce the volume administered compared to encapsulated adsorbent for oral administration, and be easy to take. | 12-26-2013 |
| 20140004190 | Solid Dosage Forms of Bendamustine | 01-02-2014 |
| 20140004191 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION | 01-02-2014 |
| 20140023705 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 01-23-2014 |
| 20140023706 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 01-23-2014 |
| 20140023707 | Co-Processed Carbohydrate System as a Quick-Dissolve Matrix for Solid Dosage Forms - The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds. | 01-23-2014 |
| 20140030325 | LONG-ACTING AND CONTROLLED RELEASE FORMULATIONS OF 2-[(3-CHLOROPHENYL) AMINO] PHENYLACETIC ACID - Formulation of long-acting and controlled release preparations of 2-[(3-chlorophenyl)amino] phenylacetic acid (23CPPA) are disclosed. Long-acting preparations comprise a slow-release formulation coated onto a pharmaceutical composition containing 23CPPA, protect against gastric irritation, slow absorption of 23CPPA, extend release of 23CPPA, protect against excessively high 23CPPA blood concentrations, and prolong maintenance of blood concentrations of 23CPPA after administration. Controlled release formulations comprise (a) a core element which is a compressed tablet containing a therapeutic dose of 23CPPA and an amount of a solubility modulating substance that controls the release of said 23CPPA in order to provide a therapeutic level over a period of about 24 hours; and (b) on the outer surface of the core element, a sufficient amount of an enteric coating that causes the 23CPPA to release at a rate that permits the use of once-a-day dosing to maintain steady state therapeutic levels of 23CPPA. | 01-30-2014 |
| 20140030326 | EFFERVESCENT FORMULATIONS COMPRISING DEXKETOPROFEN - The present invention relates to water-soluble formulations comprising the active agent dexketoprofen and to a process for production of said formulations. The present invention also relates to pharmaceutical formulations comprising dexketoprofen which is used in symptomatic treatment of mild to moderate pains such as musculoskeletal pains, dysmenorrhoea, toothache, post-operative pains. The formulations are characterized in being in effervescent form. | 01-30-2014 |
| 20140037725 | BILAYER PHARMACEUTICAL COMPOSITIONS OF NAPROXEN - The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof. Moreover, the present invention is related to the treatment of rheumatoid arthritis, oesteoarthritis, ankylosing spondylitis, pain, primary dysmenorrhoea, acute tendinitis, bursitis and acute gout. | 02-06-2014 |
| 20140037726 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 02-06-2014 |
| 20140037727 | Tablet Of Paracetamol Containing An Encapsulated Flavorant - A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink. | 02-06-2014 |
| 20140044783 | PHARMACEUTICAL COMPOSITION COMPRISING A THIAZOLIDINEDIONE - A pharmaceutical composition comprises a combination of thiazolidinedione or a pharmaceutically acceptable salt thereof as a first pharmaceutically active ingredient and a second pharmaceutically active ingredient different from thiazolidinedione, wherein the amount of said second pharmaceutically ingredient is larger than that of the first pharmaceutically active ingredient, and wherein the combination of said first and second pharmaceutically active ingredients are provided by a first granulate comprising the first and second pharmaceutically active ingredients and optionally at least one excipient, said first granulate being present in a second granulate comprising a further pharmaceutical excipient. | 02-13-2014 |
| 20140050785 | DISSOLUTION PROPERTIES OF DRUG PRODUCTS CONTAINING OLMESARTAN MEDOXOMIL - A pharmaceutical tablet containing olmesartan medoxomil and amlodipine besylate, which has improved dissolvability. The composition contains (A) olmesartan medoxomil and (B) amlodipine besylate as active ingredients and (C) a calcium-containing additive. A method for treating or preventing hypertension by administering the pharmaceutical tablet to a patient. | 02-20-2014 |
| 20140056977 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF - The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound. | 02-27-2014 |
| 20140056978 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 02-27-2014 |
| 20140065211 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 03-06-2014 |
| 20140065212 | COATED PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB - The present invention relates to a coated pharmaceutical composition containing regorafenib, a hydrate, solvate, metabolite or pharmaceutically acceptable salt thereof or a polymorph thereof and its process of preparation and its use for treating disorders. | 03-06-2014 |
| 20140072628 | STABLE PHARMACEUTICAL COMPOSITION OF SAXAGLIPTIN - Disclosed herein is a stable pharmaceutical composition comprising a substrate having deposited on its surface a layer comprising saxagliptin or pharmaceutically acceptable salts thereof, wherein a seal coat is not present between the substrate and the saxagliptin layer. | 03-13-2014 |
| 20140079778 | Pharmaceutical Formulations Including An Amine Compound - The present invention relates to solid, semisolid, or liquid formulations comprising water soluble antioxidants that prevent or reduce formic acid and/or formyl species generation in the dosage form during the manufacturing process and/or during shelf-life storage. The formulations of the present invention prevent or reduce formation of N-formyl impurities (and gelatin crosslinking) during the manufacturing process and/or during shelf-life storage. | 03-20-2014 |
| 20140079779 | Modified Release Tranexamic Acid Formulation - A modified release dosage form for the oral administration of tranexamic acid. | 03-20-2014 |
| 20140079780 | Crush resistant delayed-release dosage forms - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 03-20-2014 |
| 20140086987 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans - Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided. | 03-27-2014 |
| 20140093563 | FEBUXOSTAT COMPOSITIONS - The present invention relates to an oral pharmaceutical composition of febuxostat which comprises an intragranular component and an extragranular component. Further, it relates to processes for the preparation of said composition and a method of using said composition. | 04-03-2014 |
| 20140093564 | PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS WITH SIMVASTATIN - The present invention is directed to novel pharmaceutical compositions comprising fixed dose combinations of a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), or a pharmaceutically acceptable salt thereof, and simvastatin, or pharmaceutically acceptable salt thereof, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes and hypercholesterolemia with such pharmaceutical compositions. In particular, the invention is directed to pharmaceutical compositions comprising fixed-dose combinations of sitagliptin phosphate and simvastatin. | 04-03-2014 |
| 20140099365 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 04-10-2014 |
| 20140099366 | Composition Containing Two Anti-Dementia Drugs - An object of the present invention is to provide, for the case of implementing a therapeutic method in which at least two kinds of anti-dementia drugs are used together, a composition that has a good therapeutic effect on dementia, and also gives excellent compliance. Another object of the present invention is to provide a composition containing at least two kinds of anti-dementia drugs, in which release of the anti-dementia drugs from the composition is controlled, whereby a combined effect of the anti-dementia drugs can be achieved well. Still another object of the present invention is to provide a composition for which the frequency of administration and the amount taken are reduced and hence compliance can be improved, and a method of manufacturing such a composition. According to the present invention, there is provided a composition containing at least two kinds of anti-dementia drugs; such a composition containing at least one sustained-release portion containing an anti-dementia drug; and such a composition containing at least one cholinesterase inhibitor, and at least one N-methyl-D-aspartate receptor antagonist. | 04-10-2014 |
| 20140105976 | PHARMACEUTICAL FORMULATIONS OF PILOCARPINE - Disclosed herein are pharmaceutical compositions comprising at least one minitablet, where the minitablet comprises a core, comprising pilocarpine, or a pharmaceutically acceptable salt thereof; and a coating layer comprising a coating polymer. | 04-17-2014 |
| 20140112987 | GASTRORESISTANT PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN - The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease. | 04-24-2014 |
| 20140127294 | ORAL SOLID FORMULATION OF COMPOUND ANTI-TUBERCULAR DRUG AND PREPARATION METHOD THEREOF - Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin. | 05-08-2014 |
| 20140134246 | RAPID DISSOLVE TABLET COMPOSITIONS FOR VAGINAL ADMINISTRATION - Disclosed herein are pharmaceutically acceptable rapid dissolve vaginal tablet compositions comprising one or more active pharmaceutical ingredients suitable for therapy via topical action or systemic absorption, and methods of making and using such compositions. | 05-15-2014 |
| 20140134247 | PHARMACEUTICAL COMPOSITION - A stable formulation of telmisartan and hydrochlorothiazide having both substances in separate units is prepared, exhibiting exceptional stability when subjecting to stress conditions. | 05-15-2014 |
| 20140154316 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 06-05-2014 |
| 20140161880 | SUSTAINED RELEASE TABLET COMPRISING PREGABALIN THROUGH TWO-PHASE RELEASE-CONTROLLING SYSTEM - Provided is a sustained release tablet having two-phase release-controlling system, which consists of a first release-controlling phase comprising pregabalin or its salt and hydroxypropyl methylcellulose; and a second release-controlling phase comprising polyethylene oxide as a swelling polymer, the first release-controlling phase being homogeneously dispersed in the second release-controlling phase. | 06-12-2014 |
| 20140170215 | ORALLY DISINTEGRATING TABLETS AND METHODS OF MANUFACTURE - A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules. | 06-19-2014 |
| 20140170216 | BUPROPION HYDROBROMIDE POLYMORPHS - Polymorphous and amorphous forms of bupropion hydrobromide are described. | 06-19-2014 |
| 20140178469 | STABLE BENZIMIDAZOLE FORMULATION - A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents. | 06-26-2014 |
| 20140178470 | DISPERSIBLE TABLET - The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt, for dispersion in water and administration via a tube to a patient with swallowing difficulties. | 06-26-2014 |
| 20140193493 | Solid Dosage Forms of Oleyl Phosphocholine - The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases, such as leishmaniasis, chagas and malaria, and cancer both in humans and animals. Specifically, the present invention relates to a solid dosage form comprising: 6 to 25 weight % of the solid dosage form oleyl phosphocholine; 20 to 35 weight % of the solid dosage form lactose; 35 to 50 weight % of the solid dosage form cellulose; 5 to 20 weight % of the solid dosage form croscarmellose; 1 to 10 weight % of the solid dosage form hydroxypropylmethyl cellulose; and 0.05 to 1 weight % of the solid dosage form of a lubricant. | 07-10-2014 |
| 20140193494 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 07-10-2014 |
| 20140193495 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-10-2014 |
| 20140193496 | INTRABUCCALLY RAPIDLY DISINTEGRATING TABLET AND A PRODUCTION METHOD OF THE TABLETS - An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 μm, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape. | 07-10-2014 |
| 20140193497 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS CONTAINING DICLOFENAC - A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component. | 07-10-2014 |
| 20140199392 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 07-17-2014 |
| 20140212487 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising ledipasvir, wherein ledipasvir is dispersed within a polymer matrix formed by a pharmaceutically acceptable polymer, and further wherein ledipasvir is substantially amorphous. Also disclosed are pharmaceutical compositions comprising solid dispersion and methods of using the solid dispersion. | 07-31-2014 |
| 20140212488 | ORAL TABLET FORMULATION CONSISTING OF IMMEDIATE RELEASE ROSUVASTATIN AND EXTENDED RELEASE METFORMIN - A solid dosage product and formulation containing a fixed combination of rosuvastatin and metformin is provided here. In the formulation rosuvastatin is delivered immediately to the patient and metformin is delivered in a slower controlled fashion over a longer course of time. A method to make the formulations as well as a method to treat patients with fixed combination solid dosage form of immediate release rosuvastatin and extended release metformin are provided here. | 07-31-2014 |
| 20140220123 | PHARMACEUTICAL COMPOSITIONS COMPRISING NIACIN AND A PROCESS FOR THEIR PREPARATION - A process for the manufacture of compositions containing niacin, the process including a first compaction step of niacin or a pharmaceutically acceptable salt thereof, then a second compaction step of a dry blend comprising niacin and microcrystalline cellulose and a further compression step into tablets. Stable tablet compositions including niacin are capable of extended release of niacin. | 08-07-2014 |
| 20140220124 | COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis. | 08-07-2014 |
| 20140220125 | SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS - The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments. | 08-07-2014 |
| 20140220128 | Solid Dosage Form - A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof. | 08-07-2014 |
| 20140234415 | Tablet Dosage Forms - The present invention features tablet dosage forms comprising two or more different active ingredients. In one embodiment, a tablet dosage form of the invention comprises a first layer and a second layer, wherein the first layer comprises polymer-based solid dispersion particles having a mean particle size of no more than 200 μm. | 08-21-2014 |
| 20140234416 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 08-21-2014 |
| 20140242166 | SUSTAINED RELEASE MATRIX SYSTEMS FOR HIGHLY SOLUBLE DRUGS - Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients. | 08-28-2014 |
| 20140242167 | PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY - The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereon in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical compositions and kits are prepared in such a way that a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. | 08-28-2014 |
| 20140248346 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition. | 09-04-2014 |
| 20140248347 | PHARMACEUTICAL COMPOSITIONS OF N-METHYL-2-[3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL]-BENZAMI- DE - The present invention relates to pharmaceutical compositions containing axitinib, which is known as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or crystalline forms thereof, that protect axitinib from degradation, including photodegradation, as well as the therapeutic use of such compositions. The present invention also relates to novel photodegradants of axitinib. | 09-04-2014 |
| 20140287039 | Abiraterone Acetate Formulation - Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequestering agent as well as methods for producing and using such compositions are described. | 09-25-2014 |
| 20140287040 | Formulation - This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof. | 09-25-2014 |
| 20140287041 | Methylphenidate Extended Release Chewable Tablet - An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 09-25-2014 |
| 20140287042 | Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases - The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubric ants, colorants and combinations thereof. | 09-25-2014 |
| 20140294954 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof. | 10-02-2014 |
| 20140294955 | MISUSE PREVENTATIVE, CONTROLLED RELEASE FORMULATION - Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. | 10-02-2014 |
| 20140302137 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 10-09-2014 |
| 20140302138 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING CARBAMAZEPINE - An extended release matrix tablet for once daily administration comprising Carbamazepine or a pharmaceutically acceptable salt thereof and one or more pharmaceutical excipients and process for preparing the same and is bioequivalent to FDA approved Carbamazepine extended release tablet formulations (TEGRETOL®-XR). | 10-09-2014 |
| 20140314846 | MULTIPLE UNIT PHARMACEUTICAL FORMULATION - An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer. | 10-23-2014 |
| 20140314847 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS WITH IMPROVED BIOAVAILABILILTY - The present invention provides a controlled release oral pharmaceutical composition having a therapeutically effective amount of one or more pharmacologically active agent having low bioavailability; one or more solubilizers; one or more biocompatible swelling agents; and a swelling enhancer. The swelling agent, in combination with swelling enhancer, swells in the presence of water in gastric fluid such that the size of the dosage form is sufficiently increased to provide retention of the dosage form in the stomach of a patient, which gradually erodes within the gastrointestinal tract over a prolonged time period. | 10-23-2014 |
| 20140322320 | NOVEL COMPOSITIONS FOR EMESIS CONTROL IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY AND METHODS THEREOF - A novel approach for emesis control in cancer patients undergoing chemotherapy using pharmaceutical formulations comprising a chemotherapeutic agent and anti-emetic agent(s) in combination with different and optimized release profiles is disclosed. | 10-30-2014 |
| 20140322321 | TABLET CAPABLE OF COMBATTING MISUSE BY INJECTION - The invention relates to an oral pharmaceutical composition in the form of a sustained-release tablet comprising an active ingredient capable of being misused, which composition makes it possible to combat misuse by injection. | 10-30-2014 |
| 20140328912 | Delayed Release Tablet With Defined Core Geometry - A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released. | 11-06-2014 |
| 20140335174 | DRY-COATED TABLET CONTAINING TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM - The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell. | 11-13-2014 |
| 20140335175 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 11-13-2014 |
| 20140335176 | DISINTEGRANT-FREE DELAYED RELEASE DOXYLAMINE AND PYRIDOXINE FORMULATION AND PROCESS OF MANUFACTURING - The present invention relates to a delayed release pharmaceutical composition containing doxylamine succinate and pyridoxine HCl for treatment of nausea and vomiting during pregnancy. More specifically, the present invention concerns a disintegrant-free delayed release pharmaceutical composition for oral administration comprising a core and an enteric coating, wherein said core comprising: a) at least one pharmaceutically active ingredient, and b) at least one pharmaceutically acceptable excipient, wherein said composition provides an in vitro drug release profile of about 80% of active ingredient dissolved within 20 minutes as measured by USP Type II apparatus and also a manufacturing process of said pharmaceutical composition. | 11-13-2014 |
| 20140335177 | PHARMACEUTICAL COMPOSITION - Oral pharmaceutical formulations containing ditosylate salts of 4-quinazolineamines are described as well as methods of using the same in the treatment of disorders characterized by aberrant erbB family PTK activity. | 11-13-2014 |
| 20140341988 | ORALLY DISPERSIBLE DRUG FORMULATIONS - Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered. | 11-20-2014 |
| 20140341989 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF - Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described. | 11-20-2014 |
| 20140341990 | Controlled Release Formulations of Nisoldipine - Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions. | 11-20-2014 |
| 20140341991 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) - Disclosed are novel pharmaceutical compositions containing 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same. | 11-20-2014 |
| 20140348914 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 11-27-2014 |
| 20140348915 | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclosed. | 11-27-2014 |
| 20140377346 | BOSENTAN CONTROLLED RELEASE ORAL PREPARATION - Provided are an extended release preparation for oral administration of bosentan including bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient and a hydrophilic polymer as a sustained release excipient, and a method of manufacturing the same. Accordingly, the number of administrations of the bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof may be reduced, thereby enhancing ease of administration and patient compliance. In addition, the extended release preparation for oral administration of bosentan may be effectively manufactured. | 12-25-2014 |
| 20140377347 | IN-SITU MULTILAYERED TABLET TECHNOLOGY - The present invention relates to an in-situ multilayered tablet comprising at least one polymer layers and at least one drug layers wherein the said layers are physically separated from each other. After coming in contact with biological and/or aqueous fluids at least one of the polymer layers rapidly swells and sticks to one or more drug layers to form an in-situ multilayered tablet. Further, the polymer layer may optionally comprise a drug. Furthermore, the present invention relates to the processes for preparing said in-situ multilayered tablets. | 12-25-2014 |
| 20150010628 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF - The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders and mini-tablets and methods for treating cystic fibrosis employing the pharmaceutical composition. | 01-08-2015 |
| 20150010629 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 01-08-2015 |
| 20150017239 | METHOD FOR TREATING INTESTINAL DISEASES PRESENTING AT LEAST ONE INFLAMMATORY COMPONENT - The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions. | 01-15-2015 |
| 20150017240 | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT - An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. Methods of administering the composition are also provided. | 01-15-2015 |
| 20150030676 | STABLIZED MODIFIED RELEASE FOLIC ACID DERIVATIVE COMPOSITION, ITS THERAPEUTIC USE AND METHODS OF MANUFACTURE - This invention relates to an oral stabilized modified release pharmaceutical dosage form containing L-methylfolate calcium, which is primarily absorbed from proximal small intestine via a saturable human proton-coupled folate transporter (h-PCFT) mediated transport intended as monotherapy for the treatment of patients with MDDs and/or diagnosed with dysthymia, schizophrenia, or degenerative dementia of the Alzheimer type. | 01-29-2015 |
| 20150037406 | NOVEL CRYSTALLINE FORM OF SITAGLIPTIN SULFATE - A novel crystalline form of sitagliptin sulfate is provided. In addition, a method for obtaining the crystalline form, pharmaceutical compositions comprising the novel crystalline form and the crystalline form for use as a medicament are provided. | 02-05-2015 |
| 20150037407 | METHOD TO IMPROVE THE SAFETY OF HANDLING OF HIGH POTENCY DRUGS IN SOLID DOSAGE FORMS WITHOUT CHANGING THEIR EFFICACY - A method to improve the safety of handling of drug substances that are dispensed as solid oral dosage forms is described that does not alter the drug-release profile and the therapeutic efficacy of the pharmaceutical product. | 02-05-2015 |
| 20150037408 | Delayed Release Pharmaceutical Compositions of Salsalate - The present invention relates to modified release pharmaceutical compositions comprising salsalate. The invention also relates to processes for the preparation of such compositions. | 02-05-2015 |
| 20150044286 | ORALLY DISINTEGRATING TABLET CONTAINING BITTERNESS-MASKING GRANULES - Disclosed is a tablet containing anhydrous calcium hydrogen phosphate, granules (A) which contain sugars, and granules (B) which contain nuclear particles having a diameter of 10-500 μm, medicine and a film coating, and which have a particle diameter of 700 μm or less. The present invention enables tablet-making difficulties during the manufacture of the tablet to be suppressed. In addition, the tablet has an appropriate hardness, an excellent disintegration time, and feels very good to ingest. | 02-12-2015 |
| 20150044287 | CAPECITABINE RAPIDLY DISINTEGRATING TABLETS - There is provided a film coated pharmaceutical composition comprising 5′-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size <15-400μ), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Pharmaburst C or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet. This tablet disintegrates in water at 37° C. in a USP Disintegration Apparatus in less than 2 minutes, preferably 1 minute and have a hardness of 8-13 strong Cobb-Units. | 02-12-2015 |
| 20150050337 | Extended Release Compositions - Provided are controlled release pharmaceutical compositions comprising desvenlafaxine oxalate, one or more release rate controlling polymers, and pharmaceutically acceptable excipients. | 02-19-2015 |
| 20150056277 | DRUG DELIVERY SYSTEM - The invention relates to a time controlled, immediate release drug delivery system for oral administration of a first active ingredient to a subject in need thereof. The invention additionally relates to a dual drug delivery device, comprising the time controlled, immediate release drug delivery system according to the invention, further comprising a second coating comprising a second active ingredient. | 02-26-2015 |
| 20150056278 | Direct Compression Polymer Tablet Core - The present invention provides a tablet core which comprises at least about 95% by weight of an aliphatic amine polymer. The invention also provides a method of producing a tablet core comprising at least about 95% by weight of an aliphatic amine polymer resin The method comprises the step of compressing the aliphatic amine polymer to form the tablet core. The tablet core can further include one or more excipients. In this embodiment, the method of producing the tablet core comprises the steps of: (1) hydrating the aliphatic amine polymer to the desired moisture level; (2) blending the aliphatic amine polymer with the excipients in amounts such that the polymer comprises at least about 95% by weight of the resulting blend; and (3) compressing the blend to form the tablet core. The present invention further relates to a coated tablet comprising an aliphatic amine polymer core wherein the coating is a water based coating. | 02-26-2015 |
| 20150056279 | Controlled Release and Taste Masking Oral Pharmaceutical Compositions - The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating. | 02-26-2015 |
| 20150064249 | PHARMACEUTICAL TABLET FORMULATION FOR THE VETERINARY MEDICAL SECTOR, METHOD OF PRODUCTION AND USE THEREOF - The invention is directed to a pharmaceutical tablet formulation for the veterinary medical sector containing an instable ACE inhibitor or a pharmaceutically acceptable salt thereof as a first pharmaceutically active substance, and pimobendan or a pharmaceutically acceptable salt thereof as a second pharmaceutically active substance, comprising granules which contain carrier core particles coated with at least one layer wherein the first pharmaceutically active substance is present, the granules being embedded in a tablet matrix wherein the second pharmaceutically active substance is present. It is provided a “fixed-dose-combination” which allows to ease the treatment and administration of the medication, improves the medication compliance by reducing the pill burden to the animal holder and enables the better observation of and adherence to the therapy by decreasing the number of tablets to be administered. The lower number of tablets leads to a lower treatment failure rate, minimizes dosage mistakes and avoids confusions by false dose intake and slower development of resistance. | 03-05-2015 |
| 20150072001 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 03-12-2015 |
| 20150072002 | USE OF POLYOLS TO OBTAIN STABLE POLYMORPHOUS FORMS OF RIFAXMIN - Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described. | 03-12-2015 |
| 20150072003 | FORMULATIONS - The present invention relates to a hygroscopic matrix based composition, a process for the preparation thereof and its use in the treatment of diseases. | 03-12-2015 |
| 20150079167 | ENCASED-PELLET TABLETS - An encased-pellet tablet for an active pharmaceutical ingredient comprises an excipient layer on the outside and an inner core that is surrounded by the excipient layer. The inner core contains a plurality of coated pellets, and the coated pellets comprise pellets of the active pharmaceutical ingredient coated with a pellet coating. The excipient layer contains from about 1 wt. % to about 20 wt. % of at least one cushioning agent selected from polyhydroxyl compounds. A method for manufacturing the encased-pellet tablets involves compressing an excipient material to form a first layer; compressing a plurality of coated pellets containing an API on said first layer to form an inner core thereon and compressing additional excipient material around an exposed portion of said inner core thereby surrounding said inner core with excipient material. | 03-19-2015 |
| 20150079168 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 03-19-2015 |
| 20150086628 | ANTIRETROVIRAL COMPOSITION - The present invention provides a pharmaceutical solid oral sprinkle composition comprising one or more antiretroviral drugs, and a method of manufacturing the same. The present invention is particularly useful for treatment of an HIV infection, AIDS related complex, or AIDS. | 03-26-2015 |
| 20150093437 | NOVEL PHARMACEUTICAL COMPOSITION OF LINEZOLID - The present invention relates to a novel pharmaceutical composition of Linezolid. The present invention relates to a novel pharmaceutical composition comprising Linezolid Form III along with pharmaceutically acceptable excipients and a process to prepare the said composition. The present invention relates to an oral dosage forms for the treatment of severe infections caused by Gram-positive bacteria. | 04-02-2015 |
| 20150104510 | Aliphatic Amine Polymer Salts for Tableting - The tablets, compositions and methods of the present invention, comprising a carbonate salt of an aliphatic amine polymer and s monovalent anion can prevent or ameliorate acidosis, in particular acidosis in patients with renal disease. The tablets and compositions of the present invention maintain a disintegration time of no greater than 30 minutes at 37° C. and at pH of at least 1 for a period of at least ten weeks at 60° C. Furthermore, the tablets are stable for extended periods of time without the need for specialized storage conditions. | 04-16-2015 |
| 20150104511 | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine - The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine, festinavir and nevirapine, to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection. | 04-16-2015 |
| 20150104512 | COATED TABLETS AND THE PRODUCTION THEREOF - The present invention provides a rapidly disintegrating pharmaceutical formulation in the form of a coated tablet having increased mechanical strength, or hardness. The invention furthermore relates to a process for the production of the coated tablet and to the use of these formulations. | 04-16-2015 |
| 20150104513 | COATING FILM, AND GRANULES AND TABLETS EACH UTILIZING SAME - A coating film comprising ethyl cellulose as a component A and an (ethyl acrylate)-(methyl methacrylate) copolymer or a plasticized vinyl acetate polymer as a component B, and having a tensile elongation of 150% or more and a tensile strength of 9 N or more. | 04-16-2015 |
| 20150110869 | PHARMACEUTICAL COMPOSITION OF ENTECAVIR AND PROCESS OF MANUFACTURING - The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed. | 04-23-2015 |
| 20150118300 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse. | 04-30-2015 |
| 20150118301 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse. | 04-30-2015 |
| 20150118302 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. | 04-30-2015 |
| 20150118303 | Immediate Release Abuse-Deterrent Granulated Dosage Forms - Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. | 04-30-2015 |
| 20150125523 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 05-07-2015 |
| 20150132378 | MULTILAYERED DOSAGE FORM - The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet. | 05-14-2015 |
| 20150140094 | PHARMACEUTICAL COMPOSITIONS OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID AND ADMINISTRATION THEREOF - A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient. | 05-21-2015 |
| 20150306041 | SUSTAINED DRUG RELEASE COMPOSITION - The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent. | 10-29-2015 |
| 20150313846 | PROLONGED-RELEASE MULTIMICROPARTICULATE ORAL PHARMACEUTICAL FORM - Modified-release multimicroparticulate pharmaceutical form capable of maintaining the modified release of the active principle in an alcoholic solution and of resisting attempts at misuse. | 11-05-2015 |
| 20150313997 | IMMEDIATE RELEASE COMPOSITION RESISTANT TO ABUSE BY INTAKE OF ALCOHOL - The present invention provides immediate release pharmaceutical compositions for oral administration that are resistant to abuse by intake of alcohol. | 11-05-2015 |
| 20150320687 | PHARMACEUTICAL COMPOSITIONS CONTAINING A DGAT1 INHIBITOR - The present invention relates to a pharmaceutical composition comprising
| 11-12-2015 |
| 20150320731 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 11-12-2015 |
| 20150328150 | MEDICAL TABLET, AND MANUFACTURING METHOD AND MANUFACTURING APPARATUS FOR MEDICAL TABLET - An object is to provide a tablet manufacturing apparatus capable of supplying an IC chip to a desired position of pharmaceutical powder with a high accuracy and suppressing a positional displacement. The IC chip is supported by a positioning guide with a chip main body in a downward manner, and is held in a state of being positioned above pharmaceutical powder filled in a die hole before compression. The IC chip is supplied by a pusher. | 11-19-2015 |
| 20150328162 | PHARMACEUTICAL PREPARATIONS - The present invention relates to an improved pharmaceutical preparation comprising a dosage form of an active ingredient such as aspirin, acetaminophen, ibuprofen, naproxen sodium salt, or other NSAID, in the form of an easily chewable tablet, which when chewed is rapidly absorbed into the blood stream by the intimate presence of citric acid to yield desirably fast high blood levels. | 11-19-2015 |
| 20150328172 | Tablet Composition Comprising Cinacalcet Hydrochloride - The present invention relates to a tablet composition comprising a therapeutically effective dose of cinacalcet hydrochloride having a particle size distribution D | 11-19-2015 |
| 20150329630 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR FABRICATION OF SOLID MASSES COMPRISING POLYPEPTIDES AND/OR PROTEINS - Embodiments of the invention provide shaped masses comprising one or more drugs such as proteins or polypeptides and methods for forming such shaped masses. One embodiment provides a shaped mass comprising a drug such as a protein or polypeptide having a biological activity in the body of a mammal. The shaped mass is formed by compression of a precursor material comprising the drug wherein an amount of biologically active drug in the mass is a preserved above a minimum level. Drugs which may be incorporated into the shaped mass may include one or more glucose regulating proteins such as insulin, incretins; and immunoglobulins such as TNF-inhibiting antibodies or interleukin neutralizing antibodies. Embodiments of the shaped mass may be incorporated into a tissue penetrating member which is inserted into the intestinal wall allowing for the oral delivery of proteins and peptides which would otherwise be degraded in the intestinal tract. | 11-19-2015 |
| 20150335579 | MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE - Provided is a stable multilayer tablet containing telmisartan and hydrochlorothiazide, in which the decomposition of hydrochlorothiazide during storage, etc., is suppressed. A multilayer tablet comprising a first layer containing telmisartan, meglumine, and a moisture-absorbing substance and a second layer containing hydrochlorothiazide is provided. The moisture-absorbing substance may be a porous moisture-absorbing substance. The porous moisture-absorbing substance may be selected from light anhydrous silicic acid, synthetic aluminum silicate, natural aluminum silicate, calcium silicate, magnesium silicate, magnesium aluminosilicate, magnesium aluminometasilicate, hydrated silicon dioxide, and silicon dioxide. | 11-26-2015 |
| 20150335581 | ORODISPERSIBLE TABLETS OBTAINED BY COMPRESSION MOLDING - Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavouring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains. | 11-26-2015 |
| 20150342926 | FORMULATION FOR CO-THERAPY TREATMENT OF DIABETES - The present invention is directed a pharmaceutical compositions for co-therapy treatment and prevention of glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X. | 12-03-2015 |
| 20150342983 | COMESTIBLE CONTAINING FINELY GROUND DEMULCENT - A comestible article is disclosed that employs finely ground demulcent particles of a median particle size such that the demulcent is not readily perceived by the human tongue and in which the demulcent granules are not fully hydrated. As a result of the small particle size and lack of being fully hydrated during production, the demulcent particles exhibit faster and greater levels of hydration upon consumption, leading to quicker and more complete relief. | 12-03-2015 |
| 20150344435 | PROCESS FOR PREPARATING IVABRADINE HYDROCHLORIDE FORM IV AND METHODS OF TREATMENT OF DISEASE USING IVABRADINE HYDROCHLORIDE FORM IV - Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation, and its use as therapeutically active ingredient and pharmaceutical compositions containing lvabradine hydrochloride Form IV. | 12-03-2015 |
| 20150366801 | Rapidly Dispersible Dosage Form of Topiramate - A taste-masked rapidly dispersible dosage form of topiramate is provided. Wax coated particles of topiramate are included within a porous bound matrix. The topiramate retains its taste-masked form after dispersion in the mouth of a subject even though the particles are not coated with a polymeric material. The dosage form disperses in saliva or water in less than 2 min even though it has a high content of wax. It can be used to treat diseases or disorders that are therapeutically responsive to topiramate or a derivative thereof. | 12-24-2015 |
| 20150366802 | Rapidly Dispersible Dosage Form of Oxcarbazepine - A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof. | 12-24-2015 |
| 20150366812 | DPP-IV INHIBITOR COMBINED WITH A FURTHER ANTIDIABETIC AGENT, TABLETS COMPRISING SUCH FORMULATIONS, THEIR USE AND PROCESS FOR THEIR PREPARATION - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 12-24-2015 |
| 20150366863 | Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof - The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is glidant and/or surface active agent. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes. | 12-24-2015 |
| 20150374630 | Crush resistant delayed-release dosage forms - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 12-31-2015 |
| 20150374631 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 12-31-2015 |
| 20150374713 | STABLE PHARMECEUTICAL COMPOSITION OF AMLODIPINE AND BENAZEPRIL OR SALTS THEREOF - The present invention relates to a stable pharmaceutical composition of amiodipine and benazepril or salts thereof. In particular, the invention relates to a stable pharmaceutical composition comprising at least one amiodipine component and at least two benazepril components in which physical contact between amiodipine and benazepril components is limited. The invention also includes a process of preparing such compositions and method of treating hypertension by administering the composition to a patient in need thereof. | 12-31-2015 |
| 20150374732 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF - The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein. | 12-31-2015 |
| 20160000717 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 01-07-2016 |
| 20160000718 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 01-07-2016 |
| 20160000719 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 01-07-2016 |
| 20160000721 | GASTRO-RETENTIVE FORMULATIONS - The present invention relates to pharmaceutical compositions of the poorly soluble drugs, and pharmaceutically acceptable salts thereof, in a controlled-release gastric retained oral dosage form. Such compositions are formulated so as to deliver the majority of the incorporated drug into the stomach and upper gastrointestinal tract, with restricted drug delivery in the lower gastrointestinal tract. The dosage forms have multiple layers including an active layer with a first swellable polymer with raltegravir incorporated therein and a non-active layer with a second swellable polymer having a similar molecular weight or a higher molecular weight as the swellable polymer in the active layer. | 01-07-2016 |
| 20160015628 | HETEROCYCLIC COMPOUNDS AND THEIR USES - Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use. | 01-21-2016 |
| 20160015646 | Oral delivery system for sorafenib tosylate - The present invention relates to a gastroretentive tablet for treating unresectable hepatocellular carcinoma, comprising an enteric polymer, a nanoparticle and an excipient, wherein the nanoparticle comprises an oral multikinase inhibitor, wherein the oral multikinase inhibitor is coated with an amino methacrylate copolymer, wherein the oral multikinase inhibitor is sorafenib, and wherein the enteric polymer is methacrylic acid copolymer. The excipient is selected from a group consisting of a retarding agent, a binder, a filler, a diluent, a disintegrant, a lubricant, a colorant, a solubilizing agent, or a mixture thereof. | 01-21-2016 |
| 20160015648 | ENHANCED DRUG DELIVERY PILL - An ingestible pill includes a coating configured to dissolve in a small intestine; a core, which includes a medication-delivery element, which (a) has a compressed shape when disposed within the coating, and (b) is configured to assume, after the coating dissolves, an expanded shape; a medication; and a mucoadhesive. When unconstrained in the expanded shape, the medication-delivery element (a) is shaped so as to define first and second surfaces on opposite sides of the medication-delivery element, which have respective outer perimeters, which surround respective spaces of the respective surfaces, which spaces have respective greatest dimensions equal to between 2 and 10 cm, and each of which spaces has an area equal to at least 50% of the square of the greatest dimension; and (b) has an average thickness between the first and the second surfaces of less than 6 mm. Each of the medication and the mucoadhesive at least partially coats the first surface. | 01-21-2016 |
| 20160022591 | EXTENDED RELEASE PHARMACEUTICAL SOLID DOSAGE FORMULATIONS - A solid pharmaceutical dosage form, e.g., a tablet, is disclosed which comprises (a) a sustained released matrix core containing i) an at least sparingly water soluble active pharmaceutical ingredient, ii) a hydrophilic polymer, iii) an optional hydrophobic polymer, iv) an optional wax component, and v) optional diluent; and (b) a semi-permeable functional film coating surrounding the core, wherein the dosage form is substantially resistant to dose dumping when administered in the presence of ethanol. A method for making the dosage form is also provided in which the dosage form is coated with a semi-permeable coating. | 01-28-2016 |
| 20160022621 | COMPOSITION FOR ORAL ADMINISTRATION FOR BINDING ALDEHYDES IN THE GASTROINTESTINAL TRACT - The present invention relates to a non-toxic composition containing one or more cysteine compounds selected from L- or D-cysteine, N-acetyl cysteine, and the pharmaceutically acceptable salts thereof, for decreasing the risk of a subject contracting cancer of the stomach, the small intestine and the colon, by locally binding aldehydes present in the stomach, and optionally also separately the aldehydes carried to the small intestine or the colon, or both, whereby the composition is formulated with the help of two or more additives into controlled-release tablets containing at least one additive selected from cationic and gel-forming polymers, which tablets are formed from two or more separate layers with different release profiles, whereby the cysteine compounds are added both into the inner layer(s) and into the tablet material surrounding these. | 01-28-2016 |
| 20160022661 | Dosage Form Comprising Crizotinib - The invention relates to a method of preparing a tablet, preferably a tablet for immediate release and having a high drug load, containing crizotinib in form of the free base and lubricant, both in specific amounts. The invention further relates to a tablet obtainable by said method. | 01-28-2016 |
| 20160022662 | Cabozantinib Dosage Form and Use in the Treatment of Cancer - This invention relates to a dosage form of cabozantinib and a method of employing the dosage form to treat cancer. | 01-28-2016 |
| 20160022687 | DPP IV INHIBITOR FORMULATIONS - The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus. | 01-28-2016 |
| 20160022732 | DISSOLUTION STABILITY OF CALCIUM CARBONATE TABLETS - The present invention relates to a method for the preparation of a tablet comprising at least 50% w/w of calcium carbonate, the method comprising
| 01-28-2016 |
| 20160030354 | COMBINATION TABLET WITH CHEWABLE OUTER LAYER - A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resulted decrease in the number of tablets that a patient would need to take on a daily basis. | 02-04-2016 |
| 20160030355 | OSMOTIC DRUG DELIVERY SYSTEM - An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent. | 02-04-2016 |
| 20160030356 | Stabilized Vitamin D Formulations - The present invention relates to stable solid formulations of vitamin D | 02-04-2016 |
| 20160030357 | COMPOSITION FOR MANUFACTURING ORALLY DISINTEGRATING DOSAGE FORM TO PROTECT COATING LAYER OF ACTIVE SUBSTANCE - The present invention relates to a method of manufacturing an orally disintegrating dosage form which masks a bitter or unpleasant taste. A composition including a ratio of excipients and a coated active substance prevents a coating layer on the active substance from being destroyed during manufacture. | 02-04-2016 |
| 20160030358 | Solid Dosage Form of Coated Bisphosphonate Particles - A solid dosage form comprises coated particles of bisphosphonate or a pharmaceutically acceptable analogue or derivative thereof. | 02-04-2016 |
| 20160030436 | MOSAPRIDE SUSTAINED-RELEASE FORMULATION PROVIDING PHARMACOLOGICAL AND CLINICAL EFFECTS WITH ONCE-DAILY ADMINISTRATION - The formulation for oral administration of the present invention containing Mosapride or its salt is a double layer formulation consisting of a fast-release layer for rapid release of a drug and a sustained-release layer for slow release in order to simultaneously satisfy the rapid exhibition of pharmacological activities and sustained maintenance of pharmacological activities for 24 hours, wherein the high-viscosity hydroxypropyl methylcellulose (HPMC) and the low-viscosity HPMC are used in mixture such that the content of a high viscosity HPMC as a controlled-release matrix within the sustained-release layer has a higher content, thereby capable of controlling the dissolution rate in the regions having different pH values within the gastrointestinal tract and/or the retention time in the gastrointestinal tract. Additionally, the formulation of the present invention is a small-sized preparation with a total weight of 200 mg or less, preferably from 150 mg to 160 mg, thus capable of improving drug compliance of patients. | 02-04-2016 |
| 20160038410 | ENCAPSULATION OF PHARMACEUTICALS FOR TASTE MASKING IN CHEWABLE TABLETS - The present disclosure relates to the use of polymers to coat bitter-tasting active pharmaceutical ingredients in a manner that masks the bitter taste of these compounds. Taste masked pharmaceutical formulations in which the particles of pharmaceutically active ingredients are coated with polymers or ion exchange resins are disclosed. The formulations provide taste masked pharmaceutical formulations in which the rapid disintegration of tablets is preserved. A method for preparing such coated particles in a fluidized bed coating process is disclosed. The polymer coating may include a combination of low molecular and high molecular weight water in-soluble polymers, plasticizer and fillers, which provides for a chewable dosage form having a pleasing taste thereby improving patient compliance. | 02-11-2016 |
| 20160038424 | Bromocriptine Formulations - The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes. | 02-11-2016 |
| 20160038501 | PHARMACEUTICAL COMPOSITIONS COMPRISING BI-1356 AND METFORMIN - The present invention relates to therapeutic uses of pharmaceutical compositions or combinations of a DPP-4 inhibitor with metformin. | 02-11-2016 |
| 20160045446 | ORAL ADMINISTRATION PREPARATION WITH MASKED BITTERNESS OF SILODOSIN - The present invention provides a novel oral administration preparation that enables administration of silodosin, which is a drug with extremely strong bitterness, without a foreign-body sensation even without water, and has dissolution properties of being able to reproduce an effective blood concentration for the treatment of dysuria associated with benign prostatic hyperplasia or the like. | 02-18-2016 |
| 20160058700 | IMMEDIATE-RELEASE BOLUS - The subject of the invention is a veterinary product or a nutrition product intended in particular for the prevention and treatment of hypocalcaemia in ruminant animals. The product is in the form of a bolus comprising calcium chloride and an effervescent mixture. Advantageously, the bolus enables a high bioavailability of the calcium and does not cause lesions on the digestive tract of the animal. | 03-03-2016 |
| 20160058730 | PHARMACEUTICAL COMPOSITIONS OF TERIFLUNOMIDE - The present invention relates to stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof with colloidal silicon dioxide. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of relapsing forms of multiple sclerosis. | 03-03-2016 |
| 20160067237 | Sensory Stimulation for Cessation of Eating - Methods and compositions are provided for modifying the eating behavior of an individual. The compositions provide an oral stimulatory effect such as tingling, cooling, and/or warming. Consumption of the compositions after eating a desired amount of food may habituate the individual to ending a meal and serve to cue cessation of eating, assisting the individual with ending a meal at a time point before a signal of satiety has reached the brain. Consumption of the composition in lieu of snacking between meals may assist the individual with avoiding consumption of snacks. | 03-10-2016 |
| 20160074375 | PHARMACEUTICAL COMPOSITION CONTAINING AS AN ACTIVE INGREDIENT 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE - A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved. | 03-17-2016 |
| 20160074376 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 03-17-2016 |
| 20160081939 | ORAL PHARMACEUTICAL FORMULATION - Described herein are oral pharmaceutical formulations comprising a core component and a coating composition applied on the core component. Also described is a process for producing said oral pharmaceutical formulations. | 03-24-2016 |
| 20160081985 | CENICRIVIROC COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present disclosure relates to pharmaceutical compositions containing cenicriviroc or a salt thereof and optionally one or more additional pharmaceutically active agent, methods for the preparation thereof, and their use in the treatment of diseases or conditions, particularly viruses such as Human Immunodeficiency Virus (HIV). | 03-24-2016 |
| 20160089337 | PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDS - The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages. | 03-31-2016 |
| 20160095818 | SOLID PHARMACEUTICAL DOSAGE FORM FOR RELEASE OF AT LEAST ONE ACTIVE PHARMACEUTICAL INGREDIENT IN THE ORAL CAVITY - Solid pharmaceutical dosage form for the release of at least one Active Pharmaceutical Ingredient (API) in the oral cavity comprising a core coated by at least one film coating. The core comprises at least one API. One or more organoleptically disturbing sensations induced by one or several of the APIs and/or of inactive components of the solid pharmaceutical dosage form is/are reduced by constituents of said film coating. Said constituents comprise at least one film-forming polymer and at least one flavoring agent or at least one sweetener. | 04-07-2016 |
| 20160095819 | Pharmaceutical compositions containing flibanserin - The invention relates to oral pharmaceutical compositions containing flibanserin, methods for the preparation thereof and use thereof as a medicament. | 04-07-2016 |
| 20160101105 | HIGH DRUG LOAD TABLET - The present invention pertains to a high drug load tablet comprising as active ingredient Compound I of formula | 04-14-2016 |
| 20160106677 | PHARMACEUTICAL COMPOSITION AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and metformin XR (extended release), processes for the preparation thereof, and their use to treat certain diseases. | 04-21-2016 |
| 20160106716 | Solid Dosage Forms of Bendamustine - In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5. | 04-21-2016 |
| 20160106839 | TAMPER RESISTANT DOSAGE FORM COMPRISING INORGANIC SALT - The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing a pharmacologically active ingredient (A); an inorganic salt (B); and a polyalkylene oxide (C) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (C) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (A) is present in a controlled-release matrix comprising the inorganic salt (B) and the polyalkylene oxide (C) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (A) from said matrix comprises at least a time interval during which the release follows zero order kinetics. | 04-21-2016 |
| 20160113878 | STABLE BENZIMIDAZOLE FORMULATION - A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. | 04-28-2016 |
| 20160113879 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF - Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose. | 04-28-2016 |
| 20160113949 | DARUNAVIR FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitor darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof. | 04-28-2016 |
| 20160120813 | FUNCTIONAL POLYMER FILM-COATED PARTICLE HAVING HIGH DRUG CONTENT, TABLET CONTAINING SAME, AND METHODS FOR PRODUCTION THEREOF - Provided are functional drug-containing particles which can be compressed into tablets and in particular, to orally disintegrating tablets by employing any of a dry molding method, a wet molding method, or a humidifying drying method. The functional drug-containing particles comprise substantially spherical drug-containing particles essentially including drug and a binder, the functional drug-containing particles including a functional polymer film selected from the group consisting of an enteric film, a release control film, and a bitter taste masking film, an average particle diameter of said functional drug-containing particles being 400 μm or less, a particle diameter ratio D | 05-05-2016 |
| 20160120869 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage from comprising ticagrelor and ASA as pharmaceutically active agents, to a package for storing the solid pharmaceutical dosage form and to a solid pharmaceutical dosage form for the use in the treatment of certain diseases. | 05-05-2016 |
| 20160120900 | COMPOSITION FOR THE ORAL ADMINISTRATION OF MAGNESIUM, IN ASSOCIATION WITH A COMPOSITION FOR TREATING TYPE 2 DIABETES OR THE COMPLICATIONS THEREOF - The invention relates to a specific composition for oral administration of magnesium, for using in the treatment of type 2 diabetes or the complications thereof, in association with a composition for treating type 2 diabetes or the complications thereof. | 05-05-2016 |
| 20160128943 | CONTROLLED RELEASE CAFFEINE DOSAGE FORMS - Formulations capable of extended or sustained release of high levels of caffeine or analogs, derivatives and metabolites thereof have been developed The formulations contain at least two components capable of releasing the caffeine or related compound differing rates to maintain a desired plasma level. | 05-12-2016 |
| 20160128979 | MODIFIED RELEASE FORMULATION - Drug products in the form of modified release formulations comprising the drug substance (-)-(3aR,4S,7aR)-4-Hydroxy-4m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (AFQ056), as well as processes for making such drug products are provided. The drug products are useful in treating patients with Parkinson's disease and exhibiting L-dopa induced dyskinesia. | 05-12-2016 |
| 20160136097 | ULTRAFAST-DISINTEGRATING TABLET AND METHOD FOR MANUFACTURING SAME - An object of the present invention is to provide an orally disintegrating tablet (ultrafast-disintegrating tablet) having an extremely high disintegrability (short disintegration time), and a high tablet hardness, and to provide a simple method for the production of said ultrafast-disintegrating tablet without such a complicated process as freeze-drying. | 05-19-2016 |
| 20160136125 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONSCOMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects. | 05-19-2016 |
| 20160143850 | Oral Pharmaceutical Compositions Comprising Imatinib Mesylate - The invention relates to a granulate composition comprising 90-99.95% w/w of Imatinib mesylate, 0.05-0.2% w/w of binder and 0-8% w/w of disintegrant, wherein the granulate composition is prepared using binder in isopropyl alcohol solvent. | 05-26-2016 |
| 20160143854 | METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET - An oral dexmethylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated dexmethylphenidate-ion exchange resin complex, a barrier coated dexmethylphenidate-ion exchange resin complex-matrix, and an uncomplexed dexmethylphenidate active component. Following administration of a single dose of the extended release dexmethylphenidate chewable tablet, a therapeutically effective amount of dexmethylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile. | 05-26-2016 |
| 20160151290 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
| 20160151291 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
| 20160151356 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
| 20160151358 | Pharmaceutical Formulation Containing Gelling Agent | 06-02-2016 |
| 20160158226 | ANTITUBERCULAR COMPOSITION COMPRISING RIFAMPICIN, ISONIAZID, ETHAMBUTOL AND PYRAZINAMIDE AND ITS PROCESS OF PREPARATION - The present invention relates to a monolayer tablet for use in the treatment of tuberculosis comprising a mixture of: granules comprising isoniazid, pyrazinamide, ethambutol or a pharmaceutically acceptable salt thereof and at least one granulation binder, rifampicin in powder form, extragranular excipients, wherein all of the granules have a particle size that is less than 0.599 mm, preferably less than 0.5 mm, more preferably less than 0.422 mm, and to its process of preparation. | 06-09-2016 |
| 20160158260 | Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes - Disclosed are inhibitors of post-proline cleavage enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors are improved over those in the prior art by selection of particular classes of side chains in the P1 and/or P2 position of the inhibitor. The inhibitors can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 06-09-2016 |
| 20160166565 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FLUPIRTINE | 06-16-2016 |
| 20160166648 | Treatment of Multiple Sclerosis With Combination of Laquinimod and Interferon-Beta | 06-16-2016 |
| 20160175257 | SOLID ORAL DOSAGE FORM OF METHYLPHENIDATE OR SALTS THEREOF | 06-23-2016 |
| 20160175336 | TRADITIONAL CHINESE MEDICINE COMPOSITION, AND PREPARATION AND APPLICATION THEREOF | 06-23-2016 |
| 20160184236 | REDUCING REFLUX WHILE SLEEPING BY STIMULATING SALIVA WITH ADHERING TROCHES - A method of reducing reflux from a stomach toward a mouth while sleeping in a person in need thereof by providing to the person an adhering, bilayer troche, comprising a first layer comprising an adhesive powder, and a second layer comprising a substrate that slowly dissolves or erodes in saliva and an ingredient to be released, wherein the ingredient stimulates saliva production in the mouth; and instructing the person to adhere one or more troches in their mouth before going to sleep, thereby causing frequent swallowing of stimulated saliva while sleeping resulting in reduced reflux from the stomach. | 06-30-2016 |
| 20160193154 | Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and an Anionic Copolymer Coating | 07-07-2016 |
| 20160193276 | TRANSMUCOSAL DELIVERY OF GLATIRAMER ACETATE | 07-07-2016 |
| 20160199306 | Tamper-resistant tablet providing immediate drug release | 07-14-2016 |
| 20160199341 | BENZONATATE MODIFIED RELEASE SOLID TABLETS AND CAPSULES | 07-14-2016 |
| 20160199353 | 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-Y- LIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID BIS-(MONOETHANOLAMINE) | 07-14-2016 |
| 20160250144 | DISINTEGRATING PARTICLE COMPOSITION PRODUCED BY TWO-STAGE WET GRANULATION PROCESS, AND INTRAORALLY DISINTEGRATING TABLET CONTAINING SAME COMPOSITION | 09-01-2016 |
| 20160250145 | Rapidly Dispersible Dosage Form of Oxcarbazepine | 09-01-2016 |
| 20160250148 | TRIPULSE RELEASE STIMULANT FORMULATIONS | 09-01-2016 |
| 20160250203 | IMMEDIATE RELEASE ABUSE-DETERRENT GRANULATED DOSAGE FORMS | 09-01-2016 |
| 20160375070 | SOLID PHARMACEUTICAL COMPOSITIONS OF BROWN ALGAE - Described herein are solid pharmaceutical compositions of brown algae extracts and methods for making solid pharmaceutical compositions of brown algae extracts. In some embodiments, the brown algae extract is derived from | 12-29-2016 |
| 20160375087 | Solid Pharmaceutical Compositions for Treating HCV - The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion. | 12-29-2016 |
| 20170231989 | MULTI-LAYERED TABLET CONTAINING DRUG UNSTABLE TO LIGHT | 08-17-2017 |
| 20180021263 | METHOD OF PRODUCING A EXTRUDED COMPOSITION | 01-25-2018 |
| 20180021289 | PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYL FUMARATE FOR ADMINISTRATION AT A LOW DAILY DOSE | 01-25-2018 |
| 20190142754 | METHOD FOR MANUFACTURING ACETAMINOPHEN PREPARATION | 05-16-2019 |
